Chromophobe Renal Cell Carcinoma

Cancer MONDO:0017885 Pathograph 12 Show in embeddings browser renal cell carcinoma

Chromophobe renal cell carcinoma (chRCC) is the third most common renal cell carcinoma subtype, accounting for roughly 5-7% of renal cell carcinomas. It is mechanistically distinct from clear cell RCC at almost every level. It arises from the intercalated cells of the distal nephron rather than the proximal tubule, and it is not driven by VHL loss or HIF stabilization. Its defining molecular feature is the combined loss of whole chromosomes 1, 2, 6, 10, 13, 17 and 21 on a background of a strikingly low point-mutation burden - roughly seven chromosome losses against roughly thirty exonic somatic mutations. Recurrent point mutations converge on TP53 and on the PTEN-TSC-MTOR axis, and telomerase is reactivated by structural rearrangement of the TERT promoter rather than by the promoter point mutations seen in other cancers. The tumor cell is packed with mitochondria and retains an oxidative, electron-transport-chain-dependent metabolic phenotype - the opposite of the glycolytic Warburg shift that characterizes VHL-mutant clear cell RCC. Most chRCC behaves as a tumor of low malignant potential and is cured by nephrectomy; sarcomatoid dedifferentiation identifies the aggressive minority. Because the VHL-HIF-VEGF axis that defines clear cell RCC is absent, the antiangiogenic and checkpoint strategies built on it are a poor mechanistic fit, and mTOR inhibition is the better-motivated systemic option.

Ask OpenScientist

Ask a research question about Chromophobe Renal Cell Carcinoma. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Inheritance
9
Pathophys.
3
Histopath.
5
Phenotypes
3
Gaps
12
Pathograph
4
Genes
3
Medical Actions
3
Subtypes
2
Differentials
5
Datasets
1
Trials
2
Models
1
References
1
Deep Research
🏷

Classifications

ICD-O Morphology
Carcinoma
Harrison's Part
ONCOLOGY HEMATOLOGY
👪

Inheritance

1
Autosomal Dominant
Applies only to the hereditary minority. Sporadic chRCC is a somatically driven malignancy with no Mendelian inheritance pattern; the autosomal dominant mode applies to the FLCN-mediated Birt-Hogg-Dube predisposition.
◆

Subtypes

3
Classic (pale cell) variant NCIT:C27888
Composed predominantly of large polygonal cells with pale, finely reticulated cytoplasm, sharply drawn cell membranes and perinuclear halos. The classic variant expresses CK7 diffusely and uniformly and carries the full complement of characteristic whole-chromosome losses.
Show evidence (1 reference)
PMID:35198391 SUPPORT Human Clinical
"classic ChRCCs generally express diffuse and uniform CK7, while eosinophilic variant demonstrates more heterogeneous CK7 expression (rare or patchy)"
Distinguishes the classic from the eosinophilic variant by CK7 staining pattern, supporting the two-variant morphologic split curated here.
Eosinophilic variant NCIT:C27889
Composed predominantly of cells with granular eosinophilic cytoplasm, closely mimicking renal oncocytoma and the emerging oncocytic renal tumor entities. CK7 expression is patchy or rare rather than diffuse, which is the principal source of diagnostic difficulty in oncocytic renal tumors.
Show evidence (1 reference)
PMID:35198391 SUPPORT Human Clinical
"The major challenge in the differential diagnosis of ChRCCs includes considerations around the eosinophilic variant (of ChRCCs), where it may share overlapping features with oncocytoma"
States the diagnostic overlap between the eosinophilic variant and oncocytoma that defines this subtype's clinical significance.
Birt-Hogg-Dube syndrome-associated chRCC NCIT:C155951
FLCN hgnc:27310 HUGO Gene Nomenclature Committee (hgnc) Relation: this subtype is caused by variation in this gene This subtype is caused by variation in FLCN (hgnc:27310). hgnc:27310 is a gene from the HUGO Gene Nomenclature Committee.
chRCC arising in carriers of a germline FLCN loss-of-function variant. Tumors are characteristically multiple and bilateral, present at a younger age, and frequently take the form of hybrid oncocytic/chromophobe tumors rather than pure chRCC. Nephron-sparing surgery is prioritized because further tumors are expected over the patient's lifetime.
Show evidence (1 reference)
PMID:12459621 SUPPORT Human Clinical
"The resected tumors consisted predominantly of chromophobe renal cell carcinomas (44 of 130, 34%) or of hybrid oncocytic neoplasms that had areas reminiscent of chromophobe renal cell carcinoma and oncocytoma (65 of 130, 50%)."
Systematic pathologic review of 130 BHD renal tumors establishes chRCC and hybrid oncocytic/chromophobe tumors as the dominant histologies of this hereditary subtype.
?

Discussions and Knowledge Gaps

3
What mechanism generates the specific, recurrent loss of chromosomes 1, 2, 6, 10, 13, 17 and 21 in chromophobe renal cell carcinoma, and why does this tumor tolerate massive aneuploidy without a mutator phenotype?
KNOWLEDGE GAP OPEN chrcc_whole_chromosome_loss_mechanism
Attached to
pathophysiology#Recurrent Whole-Chromosome Loss pathophysiology#Distal Nephron Intercalated Cell Origin
The chromosome-loss signature is the defining and near-pathognomonic feature of chRCC, yet no genome-maintenance defect, replication-stress lesion or checkpoint failure has been identified as its cause. This is why the entry does not declare conformance to the genome_instability_mutation module: that module's central node models chromosomal instability arising from defective repair and failed surveillance with an accompanying elevated mutation rate, and chRCC has the aneuploidy without the mutator phenotype - roughly seven chromosome losses against roughly thirty-one exonic somatic mutations. The question is mechanistically important because extensive chromosome loss normally imposes proteotoxic stress and impairs proliferation, so whatever permits chRCC to tolerate it is likely to be a genuine feature of the disease rather than an incidental one.
Proposed experiments
Single-cell copy-number reconstruction of chRCC and normal intercalated cells
exp_chrcc_single_cell_copy_number_reconstruction
Determine whether the chromosome losses arise in a single catastrophic mis-segregation event or accumulate sequentially, and whether normal or premalignant intercalated cells show any baseline segregation fragility.
Proteostasis profiling of aneuploid chRCC cells
exp_chrcc_proteostasis_profiling_aneuploidy
Test whether chRCC cells show the proteotoxic stress response expected of highly aneuploid cells, or have adapted a tolerance mechanism.
Is the hypodiploid model of chromophobe renal cell carcinoma still accurate, given that later studies have documented frequent chromosomal gains alongside the classic loss pattern?
KNOWLEDGE GAP OPEN chrcc_hypodiploidy_versus_gains
Attached to
pathophysiology#Recurrent Whole-Chromosome Loss pathophysiology#Sarcomatoid Dedifferentiation
The long-standing description of chRCC as a hypodiploid tumor comes from comparative genomic hybridization studies of the 1990s. Higher-resolution methods have since shown a more complex and heterogeneous picture in which chromosomal gains are also frequent, and gains are specifically associated with sarcomatoid tumors and with metastatic progression through imbalanced chromosome duplication. Whether hypodiploidy remains the right summary of chRCC genomics, or is better treated as the baseline state on which later gains are superimposed during progression, is unsettled and matters for how the diagnostic copy-number test is interpreted in aggressive tumors.
Show evidence (1 reference)
PMID:33021507 SUPPORT Human Clinical
"It was thought for many years that ChRCC exhibits a hypodiploid genome. Recent studies using advanced molecular genetics techniques have shown more complex and heterogenous pattern with frequent chromosomal gains."
Directly states the revision of the hypodiploid model that this discussion records as unsettled.
Are the somatic mitochondrial DNA mutations found in most chromophobe renal cell carcinomas drivers of the tumor's oxidative phenotype, or passengers of its mitochondria-rich cell of origin?
KNOWLEDGE GAP OPEN chrcc_mtdna_driver_or_passenger
Attached to
pathophysiology#Mitochondrial Accumulation and Oxidative Metabolic Phenotype
Somatic mtDNA mutations, including frameshifting changes in complex I subunit genes, are present in the majority of chRCCs, and the tumor shows the highest mitochondrial gene expression among RCC subtypes. But the intercalated cell of origin is itself mitochondria-rich, so an oxidative phenotype is the expected inheritance rather than necessarily an acquired one. The original sequencing study explicitly declined to assign a causal role. Resolving this matters therapeutically, because targeting mitochondrial metabolism has been proposed as a chRCC-specific vulnerability and that proposal presumes a driver role.
Show evidence (1 reference)
PMID:12353267 SUPPORT Human Clinical
"Although somatic mtDNA mutations are found in chromophobe RCCs, their role in the maintenance of tumor cell phenotype or in tumorigenesis remains to be elucidated."
The source study states the open question directly, which is what this discussion records.
⚙

Pathophysiology

9
Distal Nephron Intercalated Cell Origin
chRCC arises from the intercalated cells of the distal nephron and collecting duct. This is the single fact from which most of the rest of chRCC biology follows: the intercalated cell is mitochondria-rich, which anticipates the tumor's oxidative metabolic phenotype, and it is also the presumed cell of origin of renal oncocytoma, which is why the two tumors overlap so heavily on morphology and immunophenotype. Clear cell and papillary RCC instead arise from the proximal tubule.
kidney collecting duct intercalated cell CL:1001432 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves kidney collecting duct intercalated cell (CL:1001432). CL:1001432 is a cell type from the Cell Ontology.
kidney UBERON:0002113 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in kidney (UBERON:0002113). UBERON:0002113 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Recurrent Whole-Chromosome Loss The intercalated cell of origin acquires the characteristic pattern of whole-chromosome losses.
Mitochondrial Accumulation and Oxidative Metabolic Phenotype The mitochondria-rich character of the cell of origin is retained and amplified in the tumor.
Show evidence (2 references)
PMID:25155756 SUPPORT Human Clinical
"The result is consistent that ChRCC originates from the distal nephron compared with other kidney cancers with more proximal origins."
TCGA multi-platform characterization of 66 tumors establishes the distal nephron origin of chRCC in contrast to the proximal origin of other renal cancers.
PMID:35198391 SUPPORT Human Clinical
"ChRCCs are considered to originate from the intercalated cell of distal tubules with two main morphological variants, classic and eosinophilic."
Independent review confirming the intercalated-cell origin at the cell-type level of granularity curated on this node.
Recurrent Whole-Chromosome Loss
The genomic hallmark of chRCC is the combined loss of entire chromosomes 1, 2, 6, 10, 13, 17 and 21, present in 70-93% of tumors and specific enough to be used diagnostically against renal oncocytoma. What makes this pattern mechanistically unusual is its company: chRCC carries roughly seven chromosome losses alongside only about thirty exonic somatic mutations, so the dominant oncogenic signal is copy-number rather than point mutation. Roughly 40% of tumors have no identified driver mutation in any known oncogene or tumor suppressor, which implicates the aneuploidy itself as a primary transforming event. The upstream cause of the loss pattern is not established.
chromosome segregation GO:0007059 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased chromosome segregation (GO:0007059). GO:0007059 is a biological process from the Gene Ontology. ↓ DECREASED
Downstream
TP53 Tumor Suppressor Inactivation Chromosome 17 loss removes one TP53 allele, contributing to the inactivation of the p53 axis.
mTORC1 Pathway Hyperactivation Chromosome 10 loss removes one PTEN allele, contributing to release of the brake on PI3K-AKT-mTOR signaling.
Indolent Chromophobe Tumor Growth The aneuploid genome supports outgrowth of the transformed clone.
Show evidence (3 references)
PMID:7519827 SUPPORT Human Clinical
"We conclude that a specific combination of multiple chromosomal losses characterizes chromophobe renal cell carcinomas and may help to differentiate them unequivocally from other types of kidney cancer."
The original comparative genomic hybridization study establishing the specific multi-chromosome loss signature as characteristic of chRCC.
PMID:19445733 SUPPORT Human Clinical
"we have confirmed the high specificity of monosomies of chromosomes 1, 2, 6, 10, 13, 17 and 21 in 70-93% of the chRCCs"
SNP-array analysis of 30 chRCCs quantifies the frequency of each characteristic monosomy, supporting the 70-93% figure curated here.
PMID:28614790 SUPPORT Human Clinical
"Chromophobe renal cell carcinoma (chRCC) typically shows ~7 chromosome losses (1, 2, 6, 10, 13, 17, and 21) and ~31 exonic somatic mutations, yet carries ~5%-10% metastatic incidence."
Directly quantifies the defining juxtaposition of extensive chromosome loss with a low exonic mutation burden that this node models.
TP53 Tumor Suppressor Inactivation
TP53 is the most frequently mutated gene in chRCC. Mutation is enriched in higher-grade and metastatic tumors, where it reaches 58%, against roughly a third of unselected cases. Loss of p53-mediated transcriptional control removes the DNA-damage and apoptotic checkpoint that would otherwise constrain a cell carrying this degree of aneuploidy.
signal transduction by p53 class mediator GO:0072331 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves signal transduction by p53 class mediator (GO:0072331), qualified as loss of function. GO:0072331 is a biological process from the Gene Ontology. ⇓ LOSS OF FUNCTION
Downstream
Sarcomatoid Dedifferentiation p53-axis loss is enriched in the aggressive, dedifferentiated subset.
Indolent Chromophobe Tumor Growth Loss of checkpoint control permits proliferation of the transformed clone.
Show evidence (2 references)
PMID:35198391 SUPPORT Human Clinical
"TP53 and PTEN are the two most frequently mutated genes in ChRCCs."
Establishes TP53 as the leading recurrently mutated gene in chRCC.
PMID:28614790 SUPPORT Human Clinical
"TP53 mutations (58%), PTEN mutations (24%), and imbalanced chromosome duplication (ICD, duplication of ≥ 3 chromosomes) (25%) were enriched in M-chRCC."
Quantifies TP53 mutation frequency in metastatic chRCC and its enrichment relative to non-metastatic disease.
mTORC1 Pathway Hyperactivation
Several independent lesions converge on constitutive mTORC1 signaling in chRCC: somatic PTEN loss (the second most frequently mutated gene, and 24% in metastatic tumors), somatic mutation of MTOR, TSC1, TSC2 or NRAS, and - in the hereditary setting - germline FLCN loss. This convergence is what makes mTOR inhibition the mechanistically motivated systemic option in chRCC, in contrast to the VEGF-directed strategies that follow from VHL-HIF biology in clear cell RCC.
TORC1 signaling GO:0038202 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased TORC1 signaling (GO:0038202). GO:0038202 is a biological process from the Gene Ontology. ↑ INCREASED TOR signaling GO:0031929 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased TOR signaling (GO:0031929). GO:0031929 is a biological process from the Gene Ontology. ↑ INCREASED
Animal models
Kidney-specific Flcn knockout mouse Mouse recapitulates Flcn loss activates mTOR signaling in the mouse kidney, reproducing the pathway state that PTEN, MTOR, TSC1, TSC2 and FLCN lesions converge on in human chRCC.
Kidney-targeted Bhd (Flcn) knockout mouse Mouse recapitulates Kidney-targeted Flcn inactivation activates Akt-mTOR signaling, and mTOR inhibition with rapamycin reduces kidney size and extends survival.
Downstream
Indolent Chromophobe Tumor Growth Constitutive mTORC1 output drives anabolic growth and proliferation.
Show evidence (2 references)
PMID:35198391 SUPPORT Human Clinical
"TP53 and PTEN are the two most frequently mutated genes in ChRCCs."
Supports PTEN as a leading recurrently mutated gene in chRCC. Marked PARTIAL because the review states the mutation frequency but does not itself demonstrate the downstream mTORC1 hyperactivation modeled here.
PMID:28614790 SUPPORT INDIRECT Human Clinical
"We demonstrate that TP53 mutations (58%), PTEN mutations (24%), and imbalanced chromosome duplication (ICD, duplication of ≥ 3 chromosomes) (25%) were enriched in M-chRCC."
Quantifies PTEN mutation in metastatic chRCC. INDIRECT for the same reason: it establishes the lesion, not the pathway-activation readout.
TERT Promoter Structural Rearrangement and Telomerase Reactivation
chRCC reactivates telomerase by a mechanism distinct from the point mutations and amplifications that dominate other cancers: recurrent genomic rearrangements place structural breakpoints within the TERT promoter region, juxtaposing it with strong enhancers. The result is markedly elevated TERT expression accompanied by localized hypermutation (kataegis) at the breakpoint. This is the enhancer-hijacking route to replicative immortality.
telomere maintenance via telomerase GO:0007004 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased telomere maintenance via telomerase (GO:0007004). GO:0007004 is a biological process from the Gene Ontology. ↑ INCREASED
Downstream
Indolent Chromophobe Tumor Growth Telomerase reactivation removes the replicative limit on the tumor clone.
Show evidence (1 reference)
PMID:25155756 SUPPORT Human Clinical
"Genomic rearrangements lead to recurrent structural breakpoints within TERT promoter region, which correlates with highly elevated TERT expression and manifestation of kataegis, representing a mechanism of TERT upregulation in cancer distinct from previously observed amplifications and point mutations."
TCGA whole-genome sequencing establishes the structural-rearrangement route to TERT upregulation in chRCC and explicitly contrasts it with the amplification and point-mutation mechanisms seen elsewhere.
Mitochondrial Accumulation and Oxidative Metabolic Phenotype
chRCC cells accumulate mitochondria and show near-universal upregulation of Krebs cycle and electron transport chain genes relative to normal kidney, together with the highest expression of mitochondrially encoded genes among RCC subtypes. Somatic mitochondrial DNA mutations, including frameshifting changes in complex I subunit genes, are found in the majority of tumors. This is a genuinely distinct metabolic state, not a variant of the glycolytic Warburg shift that characterizes VHL-mutant clear cell RCC, and it is why this entry does not conform to the aerobic-glycolysis node of the deregulated_cellular_energetics module. Whether the mtDNA mutations are drivers or passengers of this phenotype remains unresolved.
oxidative phosphorylation GO:0006119 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased oxidative phosphorylation (GO:0006119). GO:0006119 is a biological process from the Gene Ontology. ↑ INCREASED
Downstream
Indolent Chromophobe Tumor Growth Oxidative metabolism sustains the bioenergetic demands of the tumor.
Show evidence (2 references)
PMID:25155756 SUPPORT Human Clinical
"Combined mtDNA and gene expression analysis implicates changes in mitochondrial function as a component of the disease biology, while suggesting alternative roles for mtDNA mutations in cancers relying on oxidative phosphorylation."
TCGA analysis directly implicates altered mitochondrial function in chRCC biology and identifies the tumor as one relying on oxidative phosphorylation rather than glycolysis.
PMID:12353267 SUPPORT Human Clinical
"We found 6 somatic nucleotide changes in 5 out of the 8 chromophobe RCCs."
Whole-mitochondrial-genome sequencing establishes that somatic mtDNA mutations occur in the majority of chRCCs. Marked PARTIAL because the same study explicitly declines to attribute a causal role to them.
Indolent Chromophobe Tumor Growth
The convergent result is a solitary, well-circumscribed renal cortical tumor that is frequently large at diagnosis yet behaves as a tumor of low malignant potential, with 5-year survival reported between 78% and 100%. The dissociation between tumor size and metastatic risk distinguishes chRCC from clear cell RCC and underlies its favorable prognosis.
kidney UBERON:0002113 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in kidney (UBERON:0002113). UBERON:0002113 is an anatomical location from the Uberon multi-species anatomy ontology.
Animal models
Kidney-specific Flcn knockout mouse Mouse partially recapitulates The model generates chromophobe RCC as the predominant histology in younger mice, so it reproduces the tumor type, but not the genomic route by which humans reach it.
Downstream
Sarcomatoid Dedifferentiation A minority of tumors undergo high-grade dedifferentiation.
Show evidence (1 reference)
PMID:18813125 SUPPORT Human Clinical
"The aggregate literature suggests that chromophobe renal cell carcinoma (RCC) is biologically a tumor of low malignant potential with reported 5-year and 10-year survival rates of 78% to 100% and 80% to 90%, respectively."
Establishes the low-malignant-potential behavior and the survival range curated on this node.
Sarcomatoid Dedifferentiation
A minority of chRCC undergoes sarcomatoid (spindle-cell) transformation. This is the principal adverse prognostic event in the disease and converts an otherwise indolent tumor into aggressive, systemic-therapy-requiring disease. Unlike the conventional tumor, sarcomatoid chRCC is associated with chromosomal gains rather than the characteristic loss pattern.
Downstream
Metastatic Dissemination Dedifferentiated tumors account for a disproportionate share of metastatic chRCC.
Show evidence (2 references)
PMID:18813125 SUPPORT Human Clinical
"Sarcomatoid change was present in 12/145 (8%) tumors."
Quantifies the frequency of sarcomatoid change in a 145-case clinicopathologic series.
PMID:35198391 SUPPORT Human Clinical
"chromosomal gains are known to be associated with sarcomatoid ChRCCs"
Supports the distinct copy-number profile of sarcomatoid chRCC relative to the loss-dominated conventional tumor.
Metastatic Dissemination
Between 5% and 10% of chRCC ultimately metastasizes. Metastatic tumors are genomically distinguishable from non-metastatic ones by enrichment for TP53 mutation, PTEN mutation and imbalanced chromosome duplication - the duplication of three or more chromosomes on top of the baseline loss pattern - and the presence of these features in a primary tumor is associated with worse survival.
Show evidence (1 reference)
PMID:28614790 SUPPORT Human Clinical
"our study provides genomic insights into the metastatic progression of chRCC and identifies TP53 mutations, PTEN mutations, and ICD as high-risk features"
Identifies the three genomic features that distinguish metastatic from non-metastatic chRCC, which is what this node models.
✶

Histopathology

3
Chromophobe Renal Cell Carcinoma VERY_FREQUENT
Large polygonal cells with pale, finely reticulated cytoplasm, sharply defined plant-cell-like membranes, perinuclear halos and irregular raisinoid nuclear contours. Two morphologic variants are recognized, classic and eosinophilic.
Show evidence (1 reference)
PMID:35198391 SUPPORT Human Clinical
"ChRCCs are considered to originate from the intercalated cell of distal tubules with two main morphological variants, classic and eosinophilic."
Establishes the two-variant morphologic classification of chRCC.
CD117 and CK7 Immunoprofile VERY_FREQUENT
CD117 (KIT) positivity together with CK7 expression is the workhorse immunohistochemical panel for confirming chRCC and excluding its mimics. CK7 is diffuse and uniform in the classic variant but rare or patchy in the eosinophilic variant, which is precisely why the eosinophilic variant is difficult to separate from oncocytoma.
Show evidence (1 reference)
PMID:35198391 SUPPORT Human Clinical
"Along with positive CD117 expression, classic ChRCCs generally express diffuse and uniform CK7, while eosinophilic variant demonstrates more heterogeneous CK7 expression (rare or patchy)."
States the CD117/CK7 immunoprofile and its variant-dependent pattern.
Sarcomatoid Differentiation OCCASIONAL
Spindle-cell dedifferentiation, present in roughly 8% of resected tumors and the strongest adverse morphologic prognostic feature in chRCC.
Show evidence (1 reference)
PMID:18813125 SUPPORT Human Clinical
"Sarcomatoid change was present in 12/145 (8%) tumors."
Provides the frequency of sarcomatoid change underpinning the OCCASIONAL band assigned here (8% falls in the 5-29% range).
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Chromophobe Renal Cell Carcinoma Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

5
Digestive 1
Palpable Abdominal Mass HP:0031500 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Abdominal mass (HP:0031500). HP:0031500 is a phenotype from the Human Phenotype Ontology.
Genitourinary 1
Hematuria HP:0000790 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hematuria (HP:0000790). HP:0000790 is a phenotype from the Human Phenotype Ontology.
Constitutional 1
Flank Pain HP:0030157 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Flank pain (HP:0030157). HP:0030157 is a phenotype from the Human Phenotype Ontology.
Other 2
Renal Mass VERY_FREQUENT Renal cell carcinoma HP:0005584 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Renal cell carcinoma (HP:0005584), qualified as adult onset, mean 59.0y, range 27.0-82.0y. HP:0005584 is a phenotype from the Human Phenotype Ontology.
Onset: ADULT; mean 59.0y (range 27.0-82.0y)
Show evidence (2 references)
PMID:18813125 SUPPORT Human Clinical
"Most tumors were well circumscribed and averaged 8.0 cm (range, 1.0 to 30.0 cm); multifocality and bilaterality were present in 8% and 3% of patients."
Characterizes the renal mass in a 145-case series: well circumscribed, large, and usually unifocal and unilateral.
PMID:18813125 SUPPORT Human Clinical
"The mean age of the patients was 59 years (range, 27 to 82)"
Provides the mean age and age range underlying the adult-onset annotation on this phenotype.
Multifocal and Bilateral Renal Tumors OCCASIONAL Renal cell carcinoma HP:0005584 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Renal cell carcinoma (HP:0005584). HP:0005584 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:18813125 SUPPORT Human Clinical
"multifocality and bilaterality were present in 8% and 3% of patients"
Provides the frequencies of multifocality and bilaterality in sporadic chRCC that support the OCCASIONAL band assigned here.
🧬

Genetic Associations

4
TP53 (Somatic inactivating mutations)
Gene: TP53 hgnc:11998 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is TP53 (hgnc:11998). hgnc:11998 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: SOMATIC_DRIVER variant_origin: SOMATIC
Show evidence (1 reference)
PMID:28614790 SUPPORT Human Clinical
"TP53 mutations (58%), PTEN mutations (24%), and imbalanced chromosome duplication (ICD, duplication of ≥ 3 chromosomes) (25%) were enriched in M-chRCC."
Quantifies somatic TP53 mutation frequency in metastatic chRCC.
PTEN (Somatic loss-of-function mutations)
Gene: PTEN hgnc:9588 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is PTEN (hgnc:9588). hgnc:9588 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: SOMATIC_DRIVER variant_origin: SOMATIC
Show evidence (1 reference)
PMID:35198391 SUPPORT Human Clinical
"TP53 and PTEN are the two most frequently mutated genes in ChRCCs."
Establishes PTEN as one of the two leading recurrently mutated genes.
TERT (Somatic promoter structural rearrangement)
Gene: TERT hgnc:11730 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is TERT (hgnc:11730). hgnc:11730 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: SOMATIC_DRIVER variant_origin: SOMATIC
Show evidence (1 reference)
PMID:25155756 SUPPORT Human Clinical
"Genomic rearrangements lead to recurrent structural breakpoints within TERT promoter region, which correlates with highly elevated TERT expression and manifestation of kataegis"
Establishes the structural-rearrangement mechanism of TERT upregulation that distinguishes chRCC from other cancers.
FLCN (Germline loss-of-function mutations causing Birt-Hogg-Dube syndrome)
Gene: FLCN hgnc:27310 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is FLCN (hgnc:27310). hgnc:27310 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: CAUSATIVE variant_origin: GERMLINE
Autosomal Dominant
Show evidence (2 references)
PMID:36258004 SUPPORT Human Clinical
"Gene test confirmed a heterozygous germline FLCN nonsense mutation (c.1429C > T, p.Arg477Ter)."
Documents a germline FLCN loss-of-function variant in a patient whose resected tumors were bilateral hybrid oncocytic/chromophobe tumors and chromophobe carcinoma.
PMID:20301695 SUPPORT Human Clinical
"chromophobe histologic cell types (oncocytic hybrid tumor); clear cell carcinoma and oncocytoma are also common."
GeneReviews describes the renal tumor histology spectrum of BHD syndrome, in which chromophobe and hybrid oncocytic tumors predominate.
💊

Medical Actions

3
Nephrectomy
Action: surgical procedureNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is surgical procedure (NCIT:C15329). NCIT:C15329 is a clinical intervention from the NCI Thesaurus. Ontology label: Surgical Procedure NCIT:C15329
Surgical resection is the primary and usually curative treatment for localized chRCC. Partial nephrectomy is preferred where technically feasible, and is strongly favored in Birt-Hogg-Dube syndrome, where further tumors are expected over the patient's lifetime and renal function must be preserved across repeated operations.
Show evidence (1 reference)
PMID:39196544 SUPPORT Human Clinical
"Treatment options for RCC confined to the kidney include surgical resection with partial or radical nephrectomy"
Establishes partial or radical nephrectomy as first-line treatment for kidney-confined renal cell carcinoma.
mTOR Inhibitor Therapy
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: everolimus CHEBI:68478 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses everolimus (CHEBI:68478). CHEBI:68478 is a therapeutic agent from Chemical Entities of Biological Interest.
Everolimus is used in advanced and metastatic chRCC on the rationale that the tumor's recurrent lesions converge on mTORC1. Supporting evidence is indirect: the randomized ASPEN trial in non-clear cell RCC favored sunitinib overall while reporting treatment-effect heterogeneity across histologic subtypes, and no adequately powered randomized trial has tested mTOR inhibition in chRCC specifically.
Mechanism Target:
INHIBITS mTORC1 Pathway Hyperactivation — Everolimus inhibits mTORC1, the node on which chRCC's recurrent PTEN, MTOR, TSC1, TSC2 and NRAS lesions converge. This is the mechanism-matched systemic option in chRCC, in contrast to the VEGF-directed therapy motivated by VHL-HIF biology in clear cell RCC.
Show evidence (3 references)
PMID:26794930 SUPPORT Human Clinical
"one subtype (chromophobe) in which everolimus was associated with a longer median progression-free survival than that of sunitinib."
The chromophobe-specific result from the only randomized comparison in this setting. Marked PARTIAL because it is a subgroup finding within a trial whose overall result favored sunitinib, not a powered chRCC-specific comparison.
PMID:26794930 SUPPORT Human Clinical
"chromophobe renal cell carcinoma is often found to have activating mutations in the PI3K-mTOR pathway and preclinical sensitivity to rapamycin analogues"
States the mechanistic rationale this treatment is curated on - that chRCC carries PI3K-mTOR pathway activation and shows preclinical sensitivity to rapamycin analogues.
PMID:31335987 SUPPORT Human Clinical
"partial response was more frequent in cases with mTOR pathway mutations than in those without mutations"
Links mTOR pathway mutation status to rapalog response in renal cell carcinoma, supporting the biomarker rationale. PARTIAL because the cohort is renal cell carcinoma broadly rather than chRCC specifically.
VEGFR Tyrosine Kinase Inhibitor Therapy
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: sunitinib CHEBI:38940 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses sunitinib (CHEBI:38940). CHEBI:38940 is a therapeutic agent from Chemical Entities of Biological Interest. cabozantinib CHEBI:72317 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses cabozantinib (CHEBI:72317). CHEBI:72317 is a therapeutic agent from Chemical Entities of Biological Interest.
VEGFR tyrosine kinase inhibitors such as sunitinib and cabozantinib are used in advanced chRCC largely by extrapolation from non-clear cell RCC guidelines. The mechanistic rationale is weaker here than in clear cell RCC: chRCC lacks the VHL-HIF-VEGF axis that makes clear cell tumors hypervascular, and responses are correspondingly less predictable.
Show evidence (1 reference)
PMID:26794930 SUPPORT Human Clinical
"In patients with metastatic non-clear cell renal cell carcinoma, sunitinib improved progression-free survival compared with everolimus."
The randomized trial's primary conclusion supports sunitinib in metastatic non-clear cell RCC, the population that includes chRCC.
🔬

Diagnosis

4
Renal mass biopsy or nephrectomy specimen
chRCC is a tissue diagnosis. Core-needle biopsy or the nephrectomy specimen is the definitive material, because no blood or urine biomarker is specific for the tumor and imaging cannot reliably separate it from oncocytoma.
kidney biopsy NCIT:C51699 NCI Thesaurus (NCIT)
CD117 and CK7 immunohistochemistry
The confirmatory immunohistochemical panel. CD117 (KIT) positivity with diffuse uniform CK7 supports classic chRCC and argues against oncocytoma (CK7 focal or negative) and clear cell RCC (CD117 negative). The panel is least decisive for the eosinophilic variant, where CK7 is rare or patchy.
immunohistochemistry staining method NCIT:C23020 NCI Thesaurus (NCIT)
Show evidence (1 reference)
PMID:35198391 SUPPORT Human Clinical
"Along with positive CD117 expression, classic ChRCCs generally express diffuse and uniform CK7, while eosinophilic variant demonstrates more heterogeneous CK7 expression (rare or patchy)."
States the CD117/CK7 panel and the variant-dependent CK7 pattern that determines how decisive it is.
Copy-number testing for the characteristic chromosome losses
Cytogenetic or copy-number array testing for the combined loss of chromosomes 1, 2, 6, 10, 13, 17 and 21 resolves histologically ambiguous oncocytic renal tumors, since renal oncocytoma does not carry this pattern.
cytogenetic analysis NCIT:C18280 NCI Thesaurus (NCIT)
Show evidence (1 reference)
PMID:19445733 SUPPORT Human Clinical
"Therefore, detection of these chromosomal changes can be used for the accurate diagnosis in routine histology."
Explicitly proposes copy-number detection as a routine diagnostic aid for separating chRCC from renal oncocytoma.
Germline FLCN testing
Germline FLCN testing should be considered when chRCC is bilateral or multifocal, presents at a young age, shows hybrid oncocytic/chromophobe histology, or occurs with fibrofolliculomas or spontaneous pneumothorax - the clinical picture of Birt-Hogg-Dube syndrome.
genetic testing NCIT:C15709 NCI Thesaurus (NCIT)
Show evidence (1 reference)
PMID:12459621 SUPPORT Human Clinical
"Recognition by the pathologist of the unusual renal tumors associated with BHD may assist in the clinical diagnosis of the syndrome."
Supports using the renal tumor histology as the trigger for pursuing a BHD diagnosis. Marked PARTIAL because the paper addresses pathologic recognition rather than germline testing criteria directly.
🩻

Imaging Findings

1
Spoke-Wheel Enhancement with Central Scar
A central stellate scar with spoke-wheel-pattern enhancement on contrast-enhanced CT is a recognized but minority finding in chRCC, reported in roughly a quarter of cases. It is not specific: the same appearance is classically associated with renal oncocytoma, which is chRCC's principal benign mimic, so it cannot substitute for tissue diagnosis.
Ct
Show evidence (1 reference)
PMID:15479284 SUPPORT Human Clinical
"Enhanced CT scans showed a spoke-wheel-like enhancement with a central scar in 3 patients (27%)."
Quantifies the frequency of the spoke-wheel enhancement pattern in a retrospective imaging series of chRCC.
📊

Prevalence

1
Worldwide, as a proportion of renal cell carcinoma
Point Prevalence Unknown
Reported as 5-7% of all renal cell carcinomas. This is a proportion of RCC cases rather than a population rate, so no rate_per_100000 is asserted.
Show evidence (1 reference)
PMID:33021507 SUPPORT Human Clinical
"Chromophobe renal cell carcinoma (ChRCC) accounts for 5% to 7% of all renal cell carcinomas."
Directly states the proportion of RCC accounted for by chRCC.
🔀

Differential Diagnoses

2

Conditions with similar clinical presentations that must be differentiated from Chromophobe Renal Cell Carcinoma:

Renal oncocytoma Not Yet Curated MONDO:0003825
Overlapping Features The principal benign mimic and the reason chRCC diagnosis matters. Both tumors are thought to arise from intercalated cells, both may show a central scar with spoke-wheel enhancement on CT, and the eosinophilic variant of chRCC closely resembles oncocytoma on morphology alone.
Distinguishing Features
  • chRCC shows the characteristic combined loss of chromosomes 1, 2, 6, 10, 13, 17 and 21, which renal oncocytoma lacks; copy-number testing is diagnostic in morphologically ambiguous cases.
  • CK7 is diffuse and uniform in classic chRCC but only focal or negative in oncocytoma. This discriminator weakens for the eosinophilic variant of chRCC, where CK7 expression is rare or patchy.
Show evidence (2 references)
PMID:19445733 SUPPORT Human Clinical
"we have identified loss of chromosome 2, 10, 13, 17 and 21 as discriminating alteration between chromophobe RCCs and ROs. Therefore, detection of these chromosomal changes can be used for the accurate diagnosis in routine histology."
Establishes the specific copy-number changes that discriminate chRCC from renal oncocytoma and their use for routine diagnosis.
PMID:35198391 SUPPORT Human Clinical
"The major challenge in the differential diagnosis of ChRCCs includes considerations around the eosinophilic variant (of ChRCCs), where it may share overlapping features with oncocytoma"
Identifies oncocytoma as the principal differential, particularly for the eosinophilic variant.
Emerging oncocytic renal tumor entities
Overlapping Features Low-grade oncocytic tumor and eosinophilic solid and cystic RCC are recently recognized entities that overlap morphologically with both oncocytoma and eosinophilic chRCC, further complicating the oncocytic renal tumor differential.
Distinguishing Features
  • These entities lack the chRCC whole-chromosome loss signature and carry their own immunophenotypic and molecular profiles.
Show evidence (1 reference)
PMID:35198391 SUPPORT Human Clinical
"it may share overlapping features with oncocytoma or other recent emergent oncocytic tumors"
Supports the existence of newly recognized oncocytic tumor entities in the chRCC differential. Marked PARTIAL because the quoted abstract text names the category generally rather than the individual entities.
📊

Related Datasets

5
Gene expression and SNP profiling discriminates chromophobe renal cell carcinoma and oncocytoma geo:GSE20376
human MICROARRAY n=28
GEO series matched because chromophobe renal cell carcinoma is named in the dataset's own title. The SNP-profiling arm is the copy-number evidence underlying the characteristic monosomy pattern curated on the Recurrent Whole-Chromosome Loss node, and the paired oncocytoma samples are the comparator that makes the loss signature diagnostically useful. Relevance confirmed manually against the curated mechanism; retrieved 2026-08-15.
Detection of tetraploidization in chromophobe renal cell carcinoma: insights and pitfalls [Affymetrix OncoScan_CNV] geo:GSE140390
human MICROARRAY n=25
GEO series matched because chromophobe renal cell carcinoma is named in the dataset's own title. Directly relevant to the open question recorded in the chrcc_hypodiploidy_versus_gains discussion, since it addresses genome doubling on top of the baseline loss pattern. Relevance confirmed manually; retrieved 2026-08-15.
Genomic profiling of chromophobe renal cell carcinoma by array-based comparative genomic hybridization geo:GSE52641
human MICROARRAY n=4
GEO series matched because chromophobe renal cell carcinoma is named in the dataset's own title. Array CGH copy-number profiling, the method class that established the chromosome-loss signature. Small series (n=4). Relevance confirmed manually; retrieved 2026-08-15.
Gene expression discriminates chromophobe renal cell carcinoma and oncocytoma geo:GSE19982
human MICROARRAY n=30
PMID:20462447
GEO series matched because chromophobe renal cell carcinoma is named in the dataset's own title. Expression-based separation of chRCC from its principal benign mimic, oncocytoma - the diagnostic problem curated on the eosinophilic subtype and the CD117/CK7 immunoprofile finding. Relevance confirmed manually; retrieved 2026-08-15.
RBPJ::ALK : a novel fusion gene amplified in a metastatic sarcomatoid chromophobe renal cell carcinoma geo:GSE224415
human n=3
GEO series matched because sarcomatoid chromophobe renal cell carcinoma is named in the dataset's own title. Relevant to the Sarcomatoid Dedifferentiation and Metastatic Dissemination nodes. Single-case series (n=3), so it illustrates rather than establishes the sarcomatoid genomic profile. Relevance confirmed manually; retrieved 2026-08-15.
🔬

Clinical Trials

1
NCT01108445 PHASE_II COMPLETED
ASPEN, the randomized comparison of everolimus against sunitinib in metastatic non-clear cell RCC. The trial's overall result favored sunitinib, but chromophobe was the one histologic subtype in which everolimus was associated with longer median progression-free survival - the main clinical evidence behind mTOR inhibition in advanced chRCC.
Show evidence (1 reference)
clinicaltrials:NCT01108445 SUPPORT Human Clinical
"To compare the anti-tumor activity of everolimus and sunitinib in subjects with metastatic renal cell carcinoma (mRCC) with non-clear cell pathology."
The trial's own statement of objective. Marked PARTIAL because it establishes the comparison and population but not the chromophobe subgroup result, which is cited from the published report (PMID:26794930).
🐁

Animal Models

2
Kidney-specific Flcn knockout mouse
Kidney-specific disruption of mouse Flcn produces renal cysts followed by early-onset, highly penetrant renal neoplasia in which chromophobe RCC is the predominant histology in mice under one year of age. mTOR and TGF-beta signaling are upregulated in the resulting tumors, and ten months of rapamycin treatment suppresses tumor growth - the preclinical basis for mTOR inhibition in FLCN-driven renal tumors.
Species
Mouse
Genotype
Conditional Flcn knockout targeted to the renal proximal tubule
Genes
FLCN hgnc:27310 HUGO Gene Nomenclature Committee (hgnc) Relation: this experimental model concerns this gene This experimental model concerns FLCN (hgnc:27310). hgnc:27310 is a gene from the HUGO Gene Nomenclature Committee.
Publication
PMID:26083655
Pathograph links
mTORC1 Pathway Hyperactivation recapitulates fidelity: moderate Flcn loss activates mTOR signaling in the mouse kidney, reproducing the pathway state that PTEN, MTOR, TSC1, TSC2 and FLCN lesions converge on in human chRCC.
Limitations: The model routes to mTORC1 activation exclusively through FLCN loss, so it represents the hereditary Birt-Hogg-Dube arm rather than the somatic PTEN and MTOR-pathway mutations that drive sporadic disease.
Readouts
Renal tumor growth under rapamycin treatment
Direction: DECREASED
Interpretation: Pharmacologic mTOR inhibition suppresses tumor growth, confirming the tumors depend on the mTOR signaling state modeled by this node.
Show evidence (1 reference)
PMID:26083655 SUPPORT Model Organism
"Treatment of knockout mice with the mTOR inhibitor rapamycin for 10 months led to the suppression of tumor growth."
Reports the rapamycin rescue measurement underlying this readout.
Show evidence (1 reference)
PMID:26083655 SUPPORT Model Organism
"The mTOR and TGF-β signalings were upregulated in Flcn-deficient tumors, and these two activated pathways may synergetically cause renal tumorigenesis."
Establishes mTOR pathway upregulation in the model's tumors, supporting its use as an informative model for this mechanism node.
Indolent Chromophobe Tumor Growth partially recapitulates fidelity: low The model generates chromophobe RCC as the predominant histology in younger mice, so it reproduces the tumor type, but not the genomic route by which humans reach it.
Limitations: Two mismatches matter. The knockout is targeted to the proximal tubule, whereas human chRCC arises from distal nephron intercalated cells. And the model reproduces none of the defining sporadic genomics - the whole-chromosome loss signature, TP53 mutation, or TERT promoter rearrangement. Histology in older knockout mice shifts to papillary RCC, so the chromophobe phenotype is also age-dependent.
Readouts
Predominant renal tumor histology in mice under one year
Direction: INCREASED
Interpretation: Chromophobe RCC is the dominant tumor histology in the model at younger ages, supporting partial recapitulation of the human tumor type.
Show evidence (1 reference)
PMID:26083655 SUPPORT Model Organism
"Although the majority of the tumors were chromophobe renal cell carcinomas in affected mice under 1 year of age, papillary renal cell carcinomas predominated in the kidneys of older knockout mice."
Reports both the chromophobe-predominant histology in younger mice and the age-dependent shift that limits the model's fidelity.
Show evidence (1 reference)
PMID:26083655 SUPPORT Model Organism
"This knockout develops renal cysts and early onset (6 months) of multiple histological subtypes of renal neoplasms featuring high tumor penetrance."
Supports the model as tumor-generating and penetrant. Marked PARTIAL because it produces multiple histologic subtypes rather than chRCC alone.
Show evidence (1 reference)
PMID:26083655 SUPPORT Model Organism
"Thus, our model recapitulates human Birt-Hogg-Dubé kidney tumorigenesis, provides a valuable tool for further study of Flcn-deficient renal tumorigenesis, and tests new drugs/approaches to their treatment."
The authors' own statement of what the model recapitulates, supporting its use as an informative model for the FLCN-driven arm of chRCC.
Kidney-targeted Bhd (Flcn) knockout mouse
An earlier kidney-targeted Flcn knockout that dies of polycystic kidney disease and renal failure by three weeks, before renal tumors can develop. It is included because it provides clean evidence that Flcn loss activates the Akt-mTOR axis in kidney and that rapamycin modifies the phenotype, while illustrating why a survivable, tubule-restricted model was needed to study tumorigenesis.
Species
Mouse
Genotype
Conditional BHD (Flcn) allele with KSP-Cre kidney-targeted inactivation
Genes
FLCN hgnc:27310 HUGO Gene Nomenclature Committee (hgnc) Relation: this experimental model concerns this gene This experimental model concerns FLCN (hgnc:27310). hgnc:27310 is a gene from the HUGO Gene Nomenclature Committee.
Publication
PMID:18182616
Pathograph links
mTORC1 Pathway Hyperactivation recapitulates fidelity: moderate Kidney-targeted Flcn inactivation activates Akt-mTOR signaling, and mTOR inhibition with rapamycin reduces kidney size and extends survival.
Limitations: The mice die of renal failure by three weeks and never develop tumors, so the model speaks to the signaling consequence of Flcn loss and not to chromophobe tumorigenesis. Erk1/2 is co-activated, so the phenotype is not attributable to mTOR alone.
Readouts
Relative kidney weight under rapamycin treatment
Direction: DECREASED
Interpretation: Rapamycin reduces the kidney enlargement caused by Flcn loss, confirming mTOR dependence of the phenotype.
Show evidence (1 reference)
PMID:18182616 SUPPORT Model Organism
"Rapamycin-treated BHD knockout mice had smaller kidneys than"
Reports the rapamycin effect on relative kidney weight underlying this readout.
Show evidence (1 reference)
PMID:18182616 SUPPORT Model Organism
"Targeted BHD knockout led to the activation of Raf-extracellular signal-regulated protein kinase (Erk)1/2 and Akt-mTOR pathways in the kidneys and increased expression of cell cycle proteins and cell proliferation."
Directly demonstrates Akt-mTOR pathway activation as the consequence of Flcn loss in kidney, which is the mechanism node this link targets.
{ }

Source YAML

click to show 
name: Chromophobe Renal Cell Carcinoma
creation_date: "2026-08-15T00:00:00Z"
category: Cancer
description: >-
  Chromophobe renal cell carcinoma (chRCC) is the third most common renal cell
  carcinoma subtype, accounting for roughly 5-7% of renal cell carcinomas. It is
  mechanistically distinct from clear cell RCC at almost every level. It arises
  from the intercalated cells of the distal nephron rather than the proximal
  tubule, and it is not driven by VHL loss or HIF stabilization. Its defining
  molecular feature is the combined loss of whole chromosomes 1, 2, 6, 10, 13,
  17 and 21 on a background of a strikingly low point-mutation burden - roughly
  seven chromosome losses against roughly thirty exonic somatic mutations.
  Recurrent point mutations converge on TP53 and on the PTEN-TSC-MTOR axis, and
  telomerase is reactivated by structural rearrangement of the TERT promoter
  rather than by the promoter point mutations seen in other cancers. The tumor
  cell is packed with mitochondria and retains an oxidative,
  electron-transport-chain-dependent metabolic phenotype - the opposite of the
  glycolytic Warburg shift that characterizes VHL-mutant clear cell RCC. Most
  chRCC behaves as a tumor of low malignant potential and is cured by
  nephrectomy; sarcomatoid dedifferentiation identifies the aggressive minority.
  Because the VHL-HIF-VEGF axis that defines clear cell RCC is absent, the
  antiangiogenic and checkpoint strategies built on it are a poor mechanistic
  fit, and mTOR inhibition is the better-motivated systemic option.
categories:
- Genitourinary Cancer
- Solid Tumor
parents:
- renal cell carcinoma
synonyms:
- chromophobe renal cell carcinoma
- chromophobe cell renal carcinoma
- chromophobe carcinoma of kidney
- chromophobe renal cell adenocarcinoma
- ChRCC
has_subtypes:
- name: Classic
  display_name: Classic (pale cell) variant
  subtype_term:
    preferred_term: Classic Variant of Chromophobe Renal Cell Carcinoma
    term:
      id: NCIT:C27888
      label: Classic Variant of Chromophobe Renal Cell Carcinoma
  description: >-
    Composed predominantly of large polygonal cells with pale, finely
    reticulated cytoplasm, sharply drawn cell membranes and perinuclear halos.
    The classic variant expresses CK7 diffusely and uniformly and carries the
    full complement of characteristic whole-chromosome losses.
  evidence:
  - reference: PMID:35198391
    reference_title: "Chromophobe renal cell carcinoma: Novel molecular insights and clinicopathologic updates."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "classic ChRCCs generally express diffuse and uniform CK7, while eosinophilic variant demonstrates more heterogeneous CK7 expression (rare or patchy)"
    explanation: >-
      Distinguishes the classic from the eosinophilic variant by CK7 staining
      pattern, supporting the two-variant morphologic split curated here.
- name: Eosinophilic
  display_name: Eosinophilic variant
  subtype_term:
    preferred_term: Eosinophilic Variant of Chromophobe Renal Cell Carcinoma
    term:
      id: NCIT:C27889
      label: Eosinophilic Variant of Chromophobe Renal Cell Carcinoma
  description: >-
    Composed predominantly of cells with granular eosinophilic cytoplasm,
    closely mimicking renal oncocytoma and the emerging oncocytic renal tumor
    entities. CK7 expression is patchy or rare rather than diffuse, which is the
    principal source of diagnostic difficulty in oncocytic renal tumors.
  evidence:
  - reference: PMID:35198391
    reference_title: "Chromophobe renal cell carcinoma: Novel molecular insights and clinicopathologic updates."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The major challenge in the differential diagnosis of ChRCCs includes considerations around the eosinophilic variant (of ChRCCs), where it may share overlapping features with oncocytoma"
    explanation: >-
      States the diagnostic overlap between the eosinophilic variant and
      oncocytoma that defines this subtype's clinical significance.
- name: BHD-associated
  display_name: Birt-Hogg-Dube syndrome-associated chRCC
  subtype_term:
    preferred_term: Chromophobe Renal Cell Carcinoma Associated with Birt-Hogg-Dube Syndrome
    term:
      id: NCIT:C155951
      label: Chromophobe Renal Cell Carcinoma Associated with Birt-Hogg-Dube Syndrome
  description: >-
    chRCC arising in carriers of a germline FLCN loss-of-function variant.
    Tumors are characteristically multiple and bilateral, present at a younger
    age, and frequently take the form of hybrid oncocytic/chromophobe tumors
    rather than pure chRCC. Nephron-sparing surgery is prioritized because
    further tumors are expected over the patient's lifetime.
  genes:
  - preferred_term: FLCN
    term:
      id: hgnc:27310
      label: FLCN
  evidence:
  - reference: PMID:12459621
    reference_title: "Renal tumors in the Birt-Hogg-Dubé syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The resected tumors consisted predominantly of chromophobe renal cell carcinomas (44 of 130, 34%) or of hybrid oncocytic neoplasms that had areas reminiscent of chromophobe renal cell carcinoma and oncocytoma (65 of 130, 50%)."
    explanation: >-
      Systematic pathologic review of 130 BHD renal tumors establishes chRCC and
      hybrid oncocytic/chromophobe tumors as the dominant histologies of this
      hereditary subtype.
prevalence:
- population: Worldwide, as a proportion of renal cell carcinoma
  measure_type: POINT_PREVALENCE
  prevalence_class: UNKNOWN
  notes: >-
    Reported as 5-7% of all renal cell carcinomas. This is a proportion of RCC
    cases rather than a population rate, so no rate_per_100000 is asserted.
  evidence:
  - reference: PMID:33021507
    reference_title: "Comprehensive Review of Numerical Chromosomal Aberrations in Chromophobe Renal Cell Carcinoma Including Its Variant Morphologies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Chromophobe renal cell carcinoma (ChRCC) accounts for 5% to 7% of all renal cell carcinomas."
    explanation: Directly states the proportion of RCC accounted for by chRCC.
pathophysiology:
- name: Distal Nephron Intercalated Cell Origin
  biological_scale: CELLULAR
  description: >-
    chRCC arises from the intercalated cells of the distal nephron and collecting
    duct. This is the single fact from which most of the rest of chRCC biology
    follows: the intercalated cell is mitochondria-rich, which anticipates the
    tumor's oxidative metabolic phenotype, and it is also the presumed cell of
    origin of renal oncocytoma, which is why the two tumors overlap so heavily on
    morphology and immunophenotype. Clear cell and papillary RCC instead arise
    from the proximal tubule.
  cell_types:
  - preferred_term: kidney collecting duct intercalated cell
    term:
      id: CL:1001432
      label: kidney collecting duct intercalated cell
  locations:
  - preferred_term: kidney
    term:
      id: UBERON:0002113
      label: kidney
  downstream:
  - target: Recurrent Whole-Chromosome Loss
    description: >-
      The intercalated cell of origin acquires the characteristic pattern of
      whole-chromosome losses.
  - target: Mitochondrial Accumulation and Oxidative Metabolic Phenotype
    description: >-
      The mitochondria-rich character of the cell of origin is retained and
      amplified in the tumor.
  evidence:
  - reference: PMID:25155756
    reference_title: "The somatic genomic landscape of chromophobe renal cell carcinoma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The result is consistent that ChRCC originates from the distal nephron compared with other kidney cancers with more proximal origins."
    explanation: >-
      TCGA multi-platform characterization of 66 tumors establishes the distal
      nephron origin of chRCC in contrast to the proximal origin of other renal
      cancers.
  - reference: PMID:35198391
    reference_title: "Chromophobe renal cell carcinoma: Novel molecular insights and clinicopathologic updates."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "ChRCCs are considered to originate from the intercalated cell of distal tubules with two main morphological variants, classic and eosinophilic."
    explanation: >-
      Independent review confirming the intercalated-cell origin at the
      cell-type level of granularity curated on this node.
- name: Recurrent Whole-Chromosome Loss
  biological_scale: CELLULAR
  description: >-
    The genomic hallmark of chRCC is the combined loss of entire chromosomes 1,
    2, 6, 10, 13, 17 and 21, present in 70-93% of tumors and specific enough to
    be used diagnostically against renal oncocytoma. What makes this pattern
    mechanistically unusual is its company: chRCC carries roughly seven
    chromosome losses alongside only about thirty exonic somatic mutations, so
    the dominant oncogenic signal is copy-number rather than point mutation.
    Roughly 40% of tumors have no identified driver mutation in any known
    oncogene or tumor suppressor, which implicates the aneuploidy itself as a
    primary transforming event. The upstream cause of the loss pattern is not
    established.
  biological_processes:
  - preferred_term: chromosome segregation
    modifier: DECREASED
    term:
      id: GO:0007059
      label: chromosome segregation
  downstream:
  - target: TP53 Tumor Suppressor Inactivation
    description: >-
      Chromosome 17 loss removes one TP53 allele, contributing to the
      inactivation of the p53 axis.
  - target: mTORC1 Pathway Hyperactivation
    description: >-
      Chromosome 10 loss removes one PTEN allele, contributing to release of the
      brake on PI3K-AKT-mTOR signaling.
  - target: Indolent Chromophobe Tumor Growth
    description: >-
      The aneuploid genome supports outgrowth of the transformed clone.
  evidence:
  - reference: PMID:7519827
    reference_title: "Specific loss of chromosomes 1, 2, 6, 10, 13, 17, and 21 in chromophobe renal cell carcinomas revealed by comparative genomic hybridization."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We conclude that a specific combination of multiple chromosomal losses characterizes chromophobe renal cell carcinomas and may help to differentiate them unequivocally from other types of kidney cancer."
    explanation: >-
      The original comparative genomic hybridization study establishing the
      specific multi-chromosome loss signature as characteristic of chRCC.
  - reference: PMID:19445733
    reference_title: "High-resolution DNA copy number and gene expression analyses distinguish chromophobe renal cell carcinomas and renal oncocytomas."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "we have confirmed the high specificity of monosomies of chromosomes 1, 2, 6, 10, 13, 17 and 21 in 70-93% of the chRCCs"
    explanation: >-
      SNP-array analysis of 30 chRCCs quantifies the frequency of each
      characteristic monosomy, supporting the 70-93% figure curated here.
  - reference: PMID:28614790
    reference_title: "Genomic landscape and evolution of metastatic chromophobe renal cell carcinoma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Chromophobe renal cell carcinoma (chRCC) typically shows ~7 chromosome losses (1, 2, 6, 10, 13, 17, and 21) and ~31 exonic somatic mutations, yet carries ~5%-10% metastatic incidence."
    explanation: >-
      Directly quantifies the defining juxtaposition of extensive chromosome
      loss with a low exonic mutation burden that this node models.
- name: TP53 Tumor Suppressor Inactivation
  conforms_to: "evading_growth_suppressors#Tumor Suppressor Inactivation"
  biological_scale: MOLECULAR
  description: >-
    TP53 is the most frequently mutated gene in chRCC. Mutation is enriched in
    higher-grade and metastatic tumors, where it reaches 58%, against roughly a
    third of unselected cases. Loss of p53-mediated transcriptional control
    removes the DNA-damage and apoptotic checkpoint that would otherwise
    constrain a cell carrying this degree of aneuploidy.
  biological_processes:
  - preferred_term: signal transduction by p53 class mediator
    modifier: LOSS_OF_FUNCTION
    term:
      id: GO:0072331
      label: signal transduction by p53 class mediator
  downstream:
  - target: Sarcomatoid Dedifferentiation
    description: >-
      p53-axis loss is enriched in the aggressive, dedifferentiated subset.
  - target: Indolent Chromophobe Tumor Growth
    description: >-
      Loss of checkpoint control permits proliferation of the transformed clone.
  evidence:
  - reference: PMID:35198391
    reference_title: "Chromophobe renal cell carcinoma: Novel molecular insights and clinicopathologic updates."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "TP53 and PTEN are the two most frequently mutated genes in ChRCCs."
    explanation: >-
      Establishes TP53 as the leading recurrently mutated gene in chRCC.
  - reference: PMID:28614790
    reference_title: "Genomic landscape and evolution of metastatic chromophobe renal cell carcinoma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "TP53 mutations (58%), PTEN mutations (24%), and imbalanced chromosome duplication (ICD, duplication of ≥ 3 chromosomes) (25%) were enriched in M-chRCC."
    explanation: >-
      Quantifies TP53 mutation frequency in metastatic chRCC and its enrichment
      relative to non-metastatic disease.
- name: mTORC1 Pathway Hyperactivation
  conforms_to: "sustaining_proliferative_signaling#Constitutive Mitogenic Pathway Activation"
  biological_scale: MOLECULAR
  description: >-
    Several independent lesions converge on constitutive mTORC1 signaling in
    chRCC: somatic PTEN loss (the second most frequently mutated gene, and 24%
    in metastatic tumors), somatic mutation of MTOR, TSC1, TSC2 or NRAS, and -
    in the hereditary setting - germline FLCN loss. This convergence is what
    makes mTOR inhibition the mechanistically motivated systemic option in
    chRCC, in contrast to the VEGF-directed strategies that follow from
    VHL-HIF biology in clear cell RCC.
  biological_processes:
  - preferred_term: TORC1 signaling
    modifier: INCREASED
    term:
      id: GO:0038202
      label: TORC1 signaling
  - preferred_term: TOR signaling
    modifier: INCREASED
    term:
      id: GO:0031929
      label: TOR signaling
  downstream:
  - target: Indolent Chromophobe Tumor Growth
    description: >-
      Constitutive mTORC1 output drives anabolic growth and proliferation.
  evidence:
  - reference: PMID:35198391
    reference_title: "Chromophobe renal cell carcinoma: Novel molecular insights and clinicopathologic updates."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "TP53 and PTEN are the two most frequently mutated genes in ChRCCs."
    explanation: >-
      Supports PTEN as a leading recurrently mutated gene in chRCC. Marked
      PARTIAL because the review states the mutation frequency but does not
      itself demonstrate the downstream mTORC1 hyperactivation modeled here.
  - reference: PMID:28614790
    reference_title: "Genomic landscape and evolution of metastatic chromophobe renal cell carcinoma."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "We demonstrate that TP53 mutations (58%), PTEN mutations (24%), and imbalanced chromosome duplication (ICD, duplication of ≥ 3 chromosomes) (25%) were enriched in M-chRCC."
    explanation: >-
      Quantifies PTEN mutation in metastatic chRCC. INDIRECT for the same reason:
      it establishes the lesion, not the pathway-activation readout.
- name: TERT Promoter Structural Rearrangement and Telomerase Reactivation
  conforms_to: "enabling_replicative_immortality#Telomere Maintenance Reactivation"
  biological_scale: MOLECULAR
  description: >-
    chRCC reactivates telomerase by a mechanism distinct from the point
    mutations and amplifications that dominate other cancers: recurrent genomic
    rearrangements place structural breakpoints within the TERT promoter region,
    juxtaposing it with strong enhancers. The result is markedly elevated TERT
    expression accompanied by localized hypermutation (kataegis) at the
    breakpoint. This is the enhancer-hijacking route to replicative immortality.
  biological_processes:
  - preferred_term: telomere maintenance via telomerase
    modifier: INCREASED
    term:
      id: GO:0007004
      label: telomere maintenance via telomerase
  downstream:
  - target: Indolent Chromophobe Tumor Growth
    description: >-
      Telomerase reactivation removes the replicative limit on the tumor clone.
  evidence:
  - reference: PMID:25155756
    reference_title: "The somatic genomic landscape of chromophobe renal cell carcinoma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Genomic rearrangements lead to recurrent structural breakpoints within TERT promoter region, which correlates with highly elevated TERT expression and manifestation of kataegis, representing a mechanism of TERT upregulation in cancer distinct from previously observed amplifications and point mutations."
    explanation: >-
      TCGA whole-genome sequencing establishes the structural-rearrangement
      route to TERT upregulation in chRCC and explicitly contrasts it with the
      amplification and point-mutation mechanisms seen elsewhere.
- name: Mitochondrial Accumulation and Oxidative Metabolic Phenotype
  biological_scale: CELLULAR
  description: >-
    chRCC cells accumulate mitochondria and show near-universal upregulation of
    Krebs cycle and electron transport chain genes relative to normal kidney,
    together with the highest expression of mitochondrially encoded genes among
    RCC subtypes. Somatic mitochondrial DNA mutations, including frameshifting
    changes in complex I subunit genes, are found in the majority of tumors.
    This is a genuinely distinct metabolic state, not a variant of the
    glycolytic Warburg shift that characterizes VHL-mutant clear cell RCC, and
    it is why this entry does not conform to the aerobic-glycolysis node of the
    deregulated_cellular_energetics module. Whether the mtDNA mutations are
    drivers or passengers of this phenotype remains unresolved.
  biological_processes:
  - preferred_term: oxidative phosphorylation
    modifier: INCREASED
    term:
      id: GO:0006119
      label: oxidative phosphorylation
  downstream:
  - target: Indolent Chromophobe Tumor Growth
    description: >-
      Oxidative metabolism sustains the bioenergetic demands of the tumor.
  evidence:
  - reference: PMID:25155756
    reference_title: "The somatic genomic landscape of chromophobe renal cell carcinoma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Combined mtDNA and gene expression analysis implicates changes in mitochondrial function as a component of the disease biology, while suggesting alternative roles for mtDNA mutations in cancers relying on oxidative phosphorylation."
    explanation: >-
      TCGA analysis directly implicates altered mitochondrial function in chRCC
      biology and identifies the tumor as one relying on oxidative
      phosphorylation rather than glycolysis.
  - reference: PMID:12353267
    reference_title: "Somatic mitochondrial DNA mutations in human chromophobe renal cell carcinomas."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We found 6 somatic nucleotide changes in 5 out of the 8 chromophobe RCCs."
    explanation: >-
      Whole-mitochondrial-genome sequencing establishes that somatic mtDNA
      mutations occur in the majority of chRCCs. Marked PARTIAL because the same
      study explicitly declines to attribute a causal role to them.
- name: Indolent Chromophobe Tumor Growth
  biological_scale: TISSUE
  description: >-
    The convergent result is a solitary, well-circumscribed renal cortical tumor
    that is frequently large at diagnosis yet behaves as a tumor of low malignant
    potential, with 5-year survival reported between 78% and 100%. The
    dissociation between tumor size and metastatic risk distinguishes chRCC from
    clear cell RCC and underlies its favorable prognosis.
  locations:
  - preferred_term: kidney
    term:
      id: UBERON:0002113
      label: kidney
  downstream:
  - target: Sarcomatoid Dedifferentiation
    description: >-
      A minority of tumors undergo high-grade dedifferentiation.
  evidence:
  - reference: PMID:18813125
    reference_title: "Chromophobe renal cell carcinoma: histomorphologic characteristics and evaluation of conventional pathologic prognostic parameters in 145 cases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The aggregate literature suggests that chromophobe renal cell carcinoma (RCC) is biologically a tumor of low malignant potential with reported 5-year and 10-year survival rates of 78% to 100% and 80% to 90%, respectively."
    explanation: >-
      Establishes the low-malignant-potential behavior and the survival range
      curated on this node.
- name: Sarcomatoid Dedifferentiation
  biological_scale: TISSUE
  description: >-
    A minority of chRCC undergoes sarcomatoid (spindle-cell) transformation.
    This is the principal adverse prognostic event in the disease and converts an
    otherwise indolent tumor into aggressive, systemic-therapy-requiring disease.
    Unlike the conventional tumor, sarcomatoid chRCC is associated with
    chromosomal gains rather than the characteristic loss pattern.
  downstream:
  - target: Metastatic Dissemination
    description: >-
      Dedifferentiated tumors account for a disproportionate share of metastatic
      chRCC.
  evidence:
  - reference: PMID:18813125
    reference_title: "Chromophobe renal cell carcinoma: histomorphologic characteristics and evaluation of conventional pathologic prognostic parameters in 145 cases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Sarcomatoid change was present in 12/145 (8%) tumors."
    explanation: >-
      Quantifies the frequency of sarcomatoid change in a 145-case
      clinicopathologic series.
  - reference: PMID:35198391
    reference_title: "Chromophobe renal cell carcinoma: Novel molecular insights and clinicopathologic updates."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "chromosomal gains are known to be associated with sarcomatoid ChRCCs"
    explanation: >-
      Supports the distinct copy-number profile of sarcomatoid chRCC relative to
      the loss-dominated conventional tumor.
- name: Metastatic Dissemination
  biological_scale: ORGANISM
  description: >-
    Between 5% and 10% of chRCC ultimately metastasizes. Metastatic tumors are
    genomically distinguishable from non-metastatic ones by enrichment for TP53
    mutation, PTEN mutation and imbalanced chromosome duplication - the
    duplication of three or more chromosomes on top of the baseline loss
    pattern - and the presence of these features in a primary tumor is
    associated with worse survival.
  evidence:
  - reference: PMID:28614790
    reference_title: "Genomic landscape and evolution of metastatic chromophobe renal cell carcinoma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "our study provides genomic insights into the metastatic progression of chRCC and identifies TP53 mutations, PTEN mutations, and ICD as high-risk features"
    explanation: >-
      Identifies the three genomic features that distinguish metastatic from
      non-metastatic chRCC, which is what this node models.
histopathology:
- name: Chromophobe Renal Cell Carcinoma
  finding_term:
    preferred_term: Chromophobe Renal Cell Carcinoma
    term:
      id: NCIT:C4146
      label: Chromophobe Renal Cell Carcinoma
  frequency: VERY_FREQUENT
  description: >-
    Large polygonal cells with pale, finely reticulated cytoplasm, sharply
    defined plant-cell-like membranes, perinuclear halos and irregular
    raisinoid nuclear contours. Two morphologic variants are recognized,
    classic and eosinophilic.
  evidence:
  - reference: PMID:35198391
    reference_title: "Chromophobe renal cell carcinoma: Novel molecular insights and clinicopathologic updates."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "ChRCCs are considered to originate from the intercalated cell of distal tubules with two main morphological variants, classic and eosinophilic."
    explanation: >-
      Establishes the two-variant morphologic classification of chRCC.
- name: CD117 and CK7 Immunoprofile
  frequency: VERY_FREQUENT
  diagnostic: true
  description: >-
    CD117 (KIT) positivity together with CK7 expression is the workhorse
    immunohistochemical panel for confirming chRCC and excluding its mimics.
    CK7 is diffuse and uniform in the classic variant but rare or patchy in the
    eosinophilic variant, which is precisely why the eosinophilic variant is
    difficult to separate from oncocytoma.
  evidence:
  - reference: PMID:35198391
    reference_title: "Chromophobe renal cell carcinoma: Novel molecular insights and clinicopathologic updates."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Along with positive CD117 expression, classic ChRCCs generally express diffuse and uniform CK7, while eosinophilic variant demonstrates more heterogeneous CK7 expression (rare or patchy)."
    explanation: >-
      States the CD117/CK7 immunoprofile and its variant-dependent pattern.
- name: Sarcomatoid Differentiation
  finding_term:
    preferred_term: Sarcomatoid Features
    term:
      id: NCIT:C39694
      label: Sarcomatoid Features
  frequency: OCCASIONAL
  description: >-
    Spindle-cell dedifferentiation, present in roughly 8% of resected tumors and
    the strongest adverse morphologic prognostic feature in chRCC.
  evidence:
  - reference: PMID:18813125
    reference_title: "Chromophobe renal cell carcinoma: histomorphologic characteristics and evaluation of conventional pathologic prognostic parameters in 145 cases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Sarcomatoid change was present in 12/145 (8%) tumors."
    explanation: >-
      Provides the frequency of sarcomatoid change underpinning the OCCASIONAL
      band assigned here (8% falls in the 5-29% range).
imaging_findings:
- name: Spoke-Wheel Enhancement with Central Scar
  modality: CT
  description: >-
    A central stellate scar with spoke-wheel-pattern enhancement on
    contrast-enhanced CT is a recognized but minority finding in chRCC, reported
    in roughly a quarter of cases. It is not specific: the same appearance is
    classically associated with renal oncocytoma, which is chRCC's principal
    benign mimic, so it cannot substitute for tissue diagnosis.
  evidence:
  - reference: PMID:15479284
    reference_title: "Spoke-wheel-like enhancement as an important imaging finding of chromophobe cell renal carcinoma: a retrospective analysis on computed tomography and magnetic resonance imaging studies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Enhanced CT scans showed a spoke-wheel-like enhancement with a central scar in 3 patients (27%)."
    explanation: >-
      Quantifies the frequency of the spoke-wheel enhancement pattern in a
      retrospective imaging series of chRCC.
phenotypes:
- category: Genitourinary
  name: Renal Mass
  frequency: VERY_FREQUENT
  diagnostic: true
  description: >-
    chRCC presents as a solid renal cortical mass, usually solitary and
    unilateral in sporadic disease and typically detected incidentally on
    imaging performed for another indication. Tumors are frequently large at
    diagnosis, averaging 8 cm, without this implying the aggressive behavior
    that size would predict in clear cell RCC.
  phenotype_term:
    preferred_term: Renal cell carcinoma
    term:
      id: HP:0005584
      label: Renal cell carcinoma
    onset:
      onset_category: ADULT
      mean_age_years: 59.0
      min_age_years: 27.0
      max_age_years: 82.0
      notes: >-
        Mean age and range from a 145-case surgical series. chRCC is an
        adult-onset tumor, on average somewhat younger than clear cell RCC.
  evidence:
  - reference: PMID:18813125
    reference_title: "Chromophobe renal cell carcinoma: histomorphologic characteristics and evaluation of conventional pathologic prognostic parameters in 145 cases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Most tumors were well circumscribed and averaged 8.0 cm (range, 1.0 to 30.0 cm); multifocality and bilaterality were present in 8% and 3% of patients."
    explanation: >-
      Characterizes the renal mass in a 145-case series: well circumscribed,
      large, and usually unifocal and unilateral.
  - reference: PMID:18813125
    reference_title: "Chromophobe renal cell carcinoma: histomorphologic characteristics and evaluation of conventional pathologic prognostic parameters in 145 cases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The mean age of the patients was 59 years (range, 27 to 82)"
    explanation: >-
      Provides the mean age and age range underlying the adult-onset annotation
      on this phenotype.
- category: Genitourinary
  name: Hematuria
  description: >-
    Gross or microscopic hematuria may occur, typically with larger or locally
    advanced tumors invading the collecting system. It forms part of the classic
    but now uncommon triad with flank pain and a palpable mass.
  phenotype_term:
    preferred_term: Hematuria
    term:
      id: HP:0000790
      label: Hematuria
- category: Genitourinary
  name: Flank Pain
  description: >-
    Flank pain is a presenting feature of larger or locally advanced tumors
    rather than of the incidentally detected small renal mass that now accounts
    for most diagnoses.
  phenotype_term:
    preferred_term: Flank pain
    term:
      id: HP:0030157
      label: Flank pain
- category: Genitourinary
  name: Palpable Abdominal Mass
  description: >-
    A palpable flank or abdominal mass is a late finding, seen with large
    tumors, and completes the classic renal cell carcinoma triad.
  phenotype_term:
    preferred_term: Abdominal mass
    term:
      id: HP:0031500
      label: Abdominal mass
- category: Genitourinary
  name: Multifocal and Bilateral Renal Tumors
  frequency: OCCASIONAL
  description: >-
    Multifocality and bilaterality occur in about 8% and 3% of sporadic cases
    respectively. When present, and particularly when combined with hybrid
    oncocytic/chromophobe histology or young age, they are the clinical signal
    that should prompt evaluation for Birt-Hogg-Dube syndrome.
  phenotype_term:
    preferred_term: Renal cell carcinoma
    term:
      id: HP:0005584
      label: Renal cell carcinoma
  evidence:
  - reference: PMID:18813125
    reference_title: "Chromophobe renal cell carcinoma: histomorphologic characteristics and evaluation of conventional pathologic prognostic parameters in 145 cases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "multifocality and bilaterality were present in 8% and 3% of patients"
    explanation: >-
      Provides the frequencies of multifocality and bilaterality in sporadic
      chRCC that support the OCCASIONAL band assigned here.
genetic:
- name: TP53
  gene_term:
    preferred_term: TP53
    term:
      id: hgnc:11998
      label: TP53
  association: Somatic inactivating mutations
  relationship_type: SOMATIC_DRIVER
  variant_origin: SOMATIC
  notes: >-
    The most frequently mutated gene in chRCC. Reported in roughly a third of
    unselected TCGA cases and 58% of metastatic tumors, where it is one of three
    genomic high-risk features.
  evidence:
  - reference: PMID:28614790
    reference_title: "Genomic landscape and evolution of metastatic chromophobe renal cell carcinoma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "TP53 mutations (58%), PTEN mutations (24%), and imbalanced chromosome duplication (ICD, duplication of ≥ 3 chromosomes) (25%) were enriched in M-chRCC."
    explanation: >-
      Quantifies somatic TP53 mutation frequency in metastatic chRCC.
- name: PTEN
  gene_term:
    preferred_term: PTEN
    term:
      id: hgnc:9588
      label: PTEN
  association: Somatic loss-of-function mutations
  relationship_type: SOMATIC_DRIVER
  variant_origin: SOMATIC
  notes: >-
    The second most frequently mutated gene in chRCC, and the somatic
    counterpart of the germline PTEN loss that predisposes to renal cell
    carcinoma in Cowden syndrome. PTEN loss releases the brake on PI3K-AKT-mTOR
    signaling and is one of three genomic high-risk features in metastatic
    disease.
  evidence:
  - reference: PMID:35198391
    reference_title: "Chromophobe renal cell carcinoma: Novel molecular insights and clinicopathologic updates."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "TP53 and PTEN are the two most frequently mutated genes in ChRCCs."
    explanation: >-
      Establishes PTEN as one of the two leading recurrently mutated genes.
- name: TERT
  gene_term:
    preferred_term: TERT
    term:
      id: hgnc:11730
      label: TERT
  association: Somatic promoter structural rearrangement
  relationship_type: SOMATIC_DRIVER
  variant_origin: SOMATIC
  notes: >-
    Upregulated in chRCC by structural rearrangement of the promoter region
    rather than by the promoter point mutations or amplifications seen in other
    tumor types. The breakpoints are accompanied by localized hypermutation
    (kataegis).
  evidence:
  - reference: PMID:25155756
    reference_title: "The somatic genomic landscape of chromophobe renal cell carcinoma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Genomic rearrangements lead to recurrent structural breakpoints within TERT promoter region, which correlates with highly elevated TERT expression and manifestation of kataegis"
    explanation: >-
      Establishes the structural-rearrangement mechanism of TERT upregulation
      that distinguishes chRCC from other cancers.
- name: FLCN
  gene_term:
    preferred_term: FLCN
    term:
      id: hgnc:27310
      label: FLCN
  association: Germline loss-of-function mutations causing Birt-Hogg-Dube syndrome
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  subtype: BHD-associated
  inheritance:
  - name: Autosomal Dominant
  notes: >-
    Germline FLCN loss of function causes Birt-Hogg-Dube syndrome, in which
    chRCC and hybrid oncocytic/chromophobe tumors are the dominant renal
    histologies. FLCN is not typically somatically mutated in sporadic chRCC, so
    this is a distinct hereditary route into the same histology.
  evidence:
  - reference: PMID:36258004
    reference_title: "Heterozygous germline FLCN mutation in Birt-Hogg-Dubé syndrome with bilateral renal hybrid oncocytic/chromophobe tumor and unilateral renal chromophobe cell carcinoma: a case report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Gene test confirmed a heterozygous germline FLCN nonsense mutation (c.1429C > T, p.Arg477Ter)."
    explanation: >-
      Documents a germline FLCN loss-of-function variant in a patient whose
      resected tumors were bilateral hybrid oncocytic/chromophobe tumors and
      chromophobe carcinoma.
  - reference: PMID:20301695
    reference_title: "Birt-Hogg-Dubé Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "chromophobe histologic cell types (oncocytic hybrid tumor); clear cell carcinoma and oncocytoma are also common."
    explanation: >-
      GeneReviews describes the renal tumor histology spectrum of BHD syndrome,
      in which chromophobe and hybrid oncocytic tumors predominate.
inheritance:
- name: Autosomal Dominant
  description: >-
    Applies only to the hereditary minority. Sporadic chRCC is a somatically
    driven malignancy with no Mendelian inheritance pattern; the autosomal
    dominant mode applies to the FLCN-mediated Birt-Hogg-Dube predisposition.
treatments:
- name: Nephrectomy
  description: >-
    Surgical resection is the primary and usually curative treatment for
    localized chRCC. Partial nephrectomy is preferred where technically
    feasible, and is strongly favored in Birt-Hogg-Dube syndrome, where further
    tumors are expected over the patient's lifetime and renal function must be
    preserved across repeated operations.
  therapeutic_modality: SURGERY
  treatment_term:
    preferred_term: surgical procedure
    term:
      id: NCIT:C15329
      label: Surgical Procedure
  evidence:
  - reference: PMID:39196544
    reference_title: "Renal Cell Carcinoma: A Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Treatment options for RCC confined to the kidney include surgical resection with partial or radical nephrectomy"
    explanation: >-
      Establishes partial or radical nephrectomy as first-line treatment for
      kidney-confined renal cell carcinoma.
- name: mTOR Inhibitor Therapy
  target_mechanisms:
  - target: mTORC1 Pathway Hyperactivation
    treatment_effect: INHIBITS
    description: >-
      Everolimus inhibits mTORC1, the node on which chRCC's recurrent PTEN,
      MTOR, TSC1, TSC2 and NRAS lesions converge. This is the
      mechanism-matched systemic option in chRCC, in contrast to the
      VEGF-directed therapy motivated by VHL-HIF biology in clear cell RCC.
  description: >-
    Everolimus is used in advanced and metastatic chRCC on the rationale that
    the tumor's recurrent lesions converge on mTORC1. Supporting evidence is
    indirect: the randomized ASPEN trial in non-clear cell RCC favored sunitinib
    overall while reporting treatment-effect heterogeneity across histologic
    subtypes, and no adequately powered randomized trial has tested mTOR
    inhibition in chRCC specifically.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: everolimus
      term:
        id: CHEBI:68478
        label: everolimus
  evidence:
  - reference: PMID:26794930
    reference_title: "Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "one subtype (chromophobe) in which everolimus was associated with a longer median progression-free survival than that of sunitinib."
    explanation: >-
      The chromophobe-specific result from the only randomized comparison in
      this setting. Marked PARTIAL because it is a subgroup finding within a
      trial whose overall result favored sunitinib, not a powered
      chRCC-specific comparison.
  - reference: PMID:26794930
    reference_title: "Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "chromophobe renal cell carcinoma is often found to have activating mutations in the PI3K-mTOR pathway and preclinical sensitivity to rapamycin analogues"
    explanation: >-
      States the mechanistic rationale this treatment is curated on - that chRCC
      carries PI3K-mTOR pathway activation and shows preclinical sensitivity to
      rapamycin analogues.
  - reference: PMID:31335987
    reference_title: "PTEN expression and mutations in TSC1, TSC2 and MTOR are associated with response to rapalogs in patients with renal cell carcinoma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "partial response was more frequent in cases with mTOR pathway mutations than in those without mutations"
    explanation: >-
      Links mTOR pathway mutation status to rapalog response in renal cell
      carcinoma, supporting the biomarker rationale. PARTIAL because the cohort
      is renal cell carcinoma broadly rather than chRCC specifically.
- name: VEGFR Tyrosine Kinase Inhibitor Therapy
  description: >-
    VEGFR tyrosine kinase inhibitors such as sunitinib and cabozantinib are used
    in advanced chRCC largely by extrapolation from non-clear cell RCC
    guidelines. The mechanistic rationale is weaker here than in clear cell RCC:
    chRCC lacks the VHL-HIF-VEGF axis that makes clear cell tumors
    hypervascular, and responses are correspondingly less predictable.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: sunitinib
      term:
        id: CHEBI:38940
        label: sunitinib
    - preferred_term: cabozantinib
      term:
        id: CHEBI:72317
        label: cabozantinib
  evidence:
  - reference: PMID:26794930
    reference_title: "Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In patients with metastatic non-clear cell renal cell carcinoma, sunitinib improved progression-free survival compared with everolimus."
    explanation: >-
      The randomized trial's primary conclusion supports sunitinib in metastatic
      non-clear cell RCC, the population that includes chRCC.
diagnosis:
- name: Renal mass biopsy or nephrectomy specimen
  description: >-
    chRCC is a tissue diagnosis. Core-needle biopsy or the nephrectomy specimen
    is the definitive material, because no blood or urine biomarker is specific
    for the tumor and imaging cannot reliably separate it from oncocytoma.
  diagnosis_term:
    preferred_term: kidney biopsy
    term:
      id: NCIT:C51699
      label: Kidney Biopsy
- name: CD117 and CK7 immunohistochemistry
  description: >-
    The confirmatory immunohistochemical panel. CD117 (KIT) positivity with
    diffuse uniform CK7 supports classic chRCC and argues against oncocytoma
    (CK7 focal or negative) and clear cell RCC (CD117 negative). The panel is
    least decisive for the eosinophilic variant, where CK7 is rare or patchy.
  diagnosis_term:
    preferred_term: immunohistochemistry staining method
    term:
      id: NCIT:C23020
      label: Immunohistochemistry Staining Method
  evidence:
  - reference: PMID:35198391
    reference_title: "Chromophobe renal cell carcinoma: Novel molecular insights and clinicopathologic updates."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Along with positive CD117 expression, classic ChRCCs generally express diffuse and uniform CK7, while eosinophilic variant demonstrates more heterogeneous CK7 expression (rare or patchy)."
    explanation: >-
      States the CD117/CK7 panel and the variant-dependent CK7 pattern that
      determines how decisive it is.
- name: Copy-number testing for the characteristic chromosome losses
  description: >-
    Cytogenetic or copy-number array testing for the combined loss of
    chromosomes 1, 2, 6, 10, 13, 17 and 21 resolves histologically ambiguous
    oncocytic renal tumors, since renal oncocytoma does not carry this pattern.
  diagnosis_term:
    preferred_term: cytogenetic analysis
    term:
      id: NCIT:C18280
      label: Cytogenetic Analysis
  evidence:
  - reference: PMID:19445733
    reference_title: "High-resolution DNA copy number and gene expression analyses distinguish chromophobe renal cell carcinomas and renal oncocytomas."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Therefore, detection of these chromosomal changes can be used for the accurate diagnosis in routine histology."
    explanation: >-
      Explicitly proposes copy-number detection as a routine diagnostic aid for
      separating chRCC from renal oncocytoma.
- name: Germline FLCN testing
  description: >-
    Germline FLCN testing should be considered when chRCC is bilateral or
    multifocal, presents at a young age, shows hybrid oncocytic/chromophobe
    histology, or occurs with fibrofolliculomas or spontaneous pneumothorax -
    the clinical picture of Birt-Hogg-Dube syndrome.
  diagnosis_term:
    preferred_term: genetic testing
    term:
      id: NCIT:C15709
      label: Genetic Testing
  evidence:
  - reference: PMID:12459621
    reference_title: "Renal tumors in the Birt-Hogg-Dubé syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Recognition by the pathologist of the unusual renal tumors associated with BHD may assist in the clinical diagnosis of the syndrome."
    explanation: >-
      Supports using the renal tumor histology as the trigger for pursuing a BHD
      diagnosis. Marked PARTIAL because the paper addresses pathologic
      recognition rather than germline testing criteria directly.
differential_diagnoses:
- name: Renal oncocytoma
  disease_term:
    preferred_term: kidney oncocytoma
    term:
      id: MONDO:0003825
      label: kidney oncocytoma
  description: >-
    The principal benign mimic and the reason chRCC diagnosis matters. Both
    tumors are thought to arise from intercalated cells, both may show a central
    scar with spoke-wheel enhancement on CT, and the eosinophilic variant of
    chRCC closely resembles oncocytoma on morphology alone.
  distinguishing_features:
  - >-
    chRCC shows the characteristic combined loss of chromosomes 1, 2, 6, 10, 13,
    17 and 21, which renal oncocytoma lacks; copy-number testing is diagnostic
    in morphologically ambiguous cases.
  - >-
    CK7 is diffuse and uniform in classic chRCC but only focal or negative in
    oncocytoma. This discriminator weakens for the eosinophilic variant of
    chRCC, where CK7 expression is rare or patchy.
  evidence:
  - reference: PMID:19445733
    reference_title: "High-resolution DNA copy number and gene expression analyses distinguish chromophobe renal cell carcinomas and renal oncocytomas."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "we have identified loss of chromosome 2, 10, 13, 17 and 21 as discriminating alteration between chromophobe RCCs and ROs. Therefore, detection of these chromosomal changes can be used for the accurate diagnosis in routine histology."
    explanation: >-
      Establishes the specific copy-number changes that discriminate chRCC from
      renal oncocytoma and their use for routine diagnosis.
  - reference: PMID:35198391
    reference_title: "Chromophobe renal cell carcinoma: Novel molecular insights and clinicopathologic updates."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The major challenge in the differential diagnosis of ChRCCs includes considerations around the eosinophilic variant (of ChRCCs), where it may share overlapping features with oncocytoma"
    explanation: >-
      Identifies oncocytoma as the principal differential, particularly for the
      eosinophilic variant.
- name: Emerging oncocytic renal tumor entities
  description: >-
    Low-grade oncocytic tumor and eosinophilic solid and cystic RCC are recently
    recognized entities that overlap morphologically with both oncocytoma and
    eosinophilic chRCC, further complicating the oncocytic renal tumor
    differential.
  distinguishing_features:
  - >-
    These entities lack the chRCC whole-chromosome loss signature and carry
    their own immunophenotypic and molecular profiles.
  evidence:
  - reference: PMID:35198391
    reference_title: "Chromophobe renal cell carcinoma: Novel molecular insights and clinicopathologic updates."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "it may share overlapping features with oncocytoma or other recent emergent oncocytic tumors"
    explanation: >-
      Supports the existence of newly recognized oncocytic tumor entities in the
      chRCC differential. Marked PARTIAL because the quoted abstract text names
      the category generally rather than the individual entities.
animal_models:
- name: Kidney-specific Flcn knockout mouse
  species: Mouse
  genotype: Conditional Flcn knockout targeted to the renal proximal tubule
  genes:
  - preferred_term: FLCN
    term:
      id: hgnc:27310
      label: FLCN
  publication: PMID:26083655
  description: >-
    Kidney-specific disruption of mouse Flcn produces renal cysts followed by
    early-onset, highly penetrant renal neoplasia in which chromophobe RCC is
    the predominant histology in mice under one year of age. mTOR and TGF-beta
    signaling are upregulated in the resulting tumors, and ten months of
    rapamycin treatment suppresses tumor growth - the preclinical basis for
    mTOR inhibition in FLCN-driven renal tumors.
  modeled_mechanisms:
  - target: mTORC1 Pathway Hyperactivation
    relationship: RECAPITULATES
    fidelity: MODERATE
    description: >-
      Flcn loss activates mTOR signaling in the mouse kidney, reproducing the
      pathway state that PTEN, MTOR, TSC1, TSC2 and FLCN lesions converge on in
      human chRCC.
    limitations: >-
      The model routes to mTORC1 activation exclusively through FLCN loss, so it
      represents the hereditary Birt-Hogg-Dube arm rather than the somatic PTEN
      and MTOR-pathway mutations that drive sporadic disease.
    readouts:
    - name: Renal tumor growth under rapamycin treatment
      target: mTORC1 Pathway Hyperactivation
      direction: DECREASED
      interpretation: >-
        Pharmacologic mTOR inhibition suppresses tumor growth, confirming the
        tumors depend on the mTOR signaling state modeled by this node.
      evidence:
      - reference: PMID:26083655
        reference_title: "Disruption of tubular Flcn expression as a mouse model for renal tumor induction."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: "Treatment of knockout mice with the mTOR inhibitor rapamycin for 10 months led to the suppression of tumor growth."
        explanation: >-
          Reports the rapamycin rescue measurement underlying this readout.
    evidence:
    - reference: PMID:26083655
      reference_title: "Disruption of tubular Flcn expression as a mouse model for renal tumor induction."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "The mTOR and TGF-β signalings were upregulated in Flcn-deficient tumors, and these two activated pathways may synergetically cause renal tumorigenesis."
      explanation: >-
        Establishes mTOR pathway upregulation in the model's tumors, supporting
        its use as an informative model for this mechanism node.
  - target: Indolent Chromophobe Tumor Growth
    relationship: PARTIALLY_RECAPITULATES
    fidelity: LOW
    description: >-
      The model generates chromophobe RCC as the predominant histology in
      younger mice, so it reproduces the tumor type, but not the genomic route
      by which humans reach it.
    limitations: >-
      Two mismatches matter. The knockout is targeted to the proximal tubule,
      whereas human chRCC arises from distal nephron intercalated cells. And the
      model reproduces none of the defining sporadic genomics - the
      whole-chromosome loss signature, TP53 mutation, or TERT promoter
      rearrangement. Histology in older knockout mice shifts to papillary RCC,
      so the chromophobe phenotype is also age-dependent.
    readouts:
    - name: Predominant renal tumor histology in mice under one year
      target: Indolent Chromophobe Tumor Growth
      direction: INCREASED
      interpretation: >-
        Chromophobe RCC is the dominant tumor histology in the model at younger
        ages, supporting partial recapitulation of the human tumor type.
      evidence:
      - reference: PMID:26083655
        reference_title: "Disruption of tubular Flcn expression as a mouse model for renal tumor induction."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: "Although the majority of the tumors were chromophobe renal cell carcinomas in affected mice under 1 year of age, papillary renal cell carcinomas predominated in the kidneys of older knockout mice."
        explanation: >-
          Reports both the chromophobe-predominant histology in younger mice and
          the age-dependent shift that limits the model's fidelity.
    evidence:
    - reference: PMID:26083655
      reference_title: "Disruption of tubular Flcn expression as a mouse model for renal tumor induction."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "This knockout develops renal cysts and early onset (6 months) of multiple histological subtypes of renal neoplasms featuring high tumor penetrance."
      explanation: >-
        Supports the model as tumor-generating and penetrant. Marked PARTIAL
        because it produces multiple histologic subtypes rather than chRCC
        alone.
  evidence:
  - reference: PMID:26083655
    reference_title: "Disruption of tubular Flcn expression as a mouse model for renal tumor induction."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Thus, our model recapitulates human Birt-Hogg-Dubé kidney tumorigenesis, provides a valuable tool for further study of Flcn-deficient renal tumorigenesis, and tests new drugs/approaches to their treatment."
    explanation: >-
      The authors' own statement of what the model recapitulates, supporting its
      use as an informative model for the FLCN-driven arm of chRCC.
- name: Kidney-targeted Bhd (Flcn) knockout mouse
  species: Mouse
  genotype: Conditional BHD (Flcn) allele with KSP-Cre kidney-targeted inactivation
  genes:
  - preferred_term: FLCN
    term:
      id: hgnc:27310
      label: FLCN
  publication: PMID:18182616
  description: >-
    An earlier kidney-targeted Flcn knockout that dies of polycystic kidney
    disease and renal failure by three weeks, before renal tumors can develop.
    It is included because it provides clean evidence that Flcn loss activates
    the Akt-mTOR axis in kidney and that rapamycin modifies the phenotype, while
    illustrating why a survivable, tubule-restricted model was needed to study
    tumorigenesis.
  modeled_mechanisms:
  - target: mTORC1 Pathway Hyperactivation
    relationship: RECAPITULATES
    fidelity: MODERATE
    description: >-
      Kidney-targeted Flcn inactivation activates Akt-mTOR signaling, and mTOR
      inhibition with rapamycin reduces kidney size and extends survival.
    limitations: >-
      The mice die of renal failure by three weeks and never develop tumors, so
      the model speaks to the signaling consequence of Flcn loss and not to
      chromophobe tumorigenesis. Erk1/2 is co-activated, so the phenotype is not
      attributable to mTOR alone.
    readouts:
    - name: Relative kidney weight under rapamycin treatment
      target: mTORC1 Pathway Hyperactivation
      direction: DECREASED
      interpretation: >-
        Rapamycin reduces the kidney enlargement caused by Flcn loss, confirming
        mTOR dependence of the phenotype.
      evidence:
      - reference: PMID:18182616
        reference_title: "Kidney-targeted Birt-Hogg-Dube gene inactivation in a mouse model: Erk1/2 and Akt-mTOR activation, cell hyperproliferation, and polycystic kidneys."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: "Rapamycin-treated BHD knockout mice had smaller kidneys than"
        explanation: >-
          Reports the rapamycin effect on relative kidney weight underlying this
          readout.
    evidence:
    - reference: PMID:18182616
      reference_title: "Kidney-targeted Birt-Hogg-Dube gene inactivation in a mouse model: Erk1/2 and Akt-mTOR activation, cell hyperproliferation, and polycystic kidneys."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Targeted BHD knockout led to the activation of Raf-extracellular signal-regulated protein kinase (Erk)1/2 and Akt-mTOR pathways in the kidneys and increased expression of cell cycle proteins and cell proliferation."
      explanation: >-
        Directly demonstrates Akt-mTOR pathway activation as the consequence of
        Flcn loss in kidney, which is the mechanism node this link targets.
clinical_trials:
- name: NCT01108445
  phase: PHASE_II
  status: COMPLETED
  description: >-
    ASPEN, the randomized comparison of everolimus against sunitinib in
    metastatic non-clear cell RCC. The trial's overall result favored sunitinib,
    but chromophobe was the one histologic subtype in which everolimus was
    associated with longer median progression-free survival - the main clinical
    evidence behind mTOR inhibition in advanced chRCC.
  evidence:
  - reference: clinicaltrials:NCT01108445
    reference_title: "A Randomized Phase II Study of Afinitor (RAD001) vs. Sutent (Sunitinib) in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma (ASPEN)"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "To compare the anti-tumor activity of everolimus and sunitinib in subjects with metastatic renal cell carcinoma (mRCC) with non-clear cell pathology."
    explanation: >-
      The trial's own statement of objective. Marked PARTIAL because it
      establishes the comparison and population but not the chromophobe subgroup
      result, which is cited from the published report (PMID:26794930).
discussions:
- discussion_id: chrcc_whole_chromosome_loss_mechanism
  prompt: >-
    What mechanism generates the specific, recurrent loss of chromosomes 1, 2,
    6, 10, 13, 17 and 21 in chromophobe renal cell carcinoma, and why does this
    tumor tolerate massive aneuploidy without a mutator phenotype?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Recurrent Whole-Chromosome Loss
  - pathophysiology#Distal Nephron Intercalated Cell Origin
  rationale: >-
    The chromosome-loss signature is the defining and near-pathognomonic feature
    of chRCC, yet no genome-maintenance defect, replication-stress lesion or
    checkpoint failure has been identified as its cause. This is why the entry
    does not declare conformance to the genome_instability_mutation module: that
    module's central node models chromosomal instability arising from defective
    repair and failed surveillance with an accompanying elevated mutation rate,
    and chRCC has the aneuploidy without the mutator phenotype - roughly seven
    chromosome losses against roughly thirty-one exonic somatic mutations. The
    question is mechanistically important because extensive chromosome loss
    normally imposes proteotoxic stress and impairs proliferation, so whatever
    permits chRCC to tolerate it is likely to be a genuine feature of the
    disease rather than an incidental one.
  proposed_experiments:
  - experiment_id: exp_chrcc_single_cell_copy_number_reconstruction
    name: Single-cell copy-number reconstruction of chRCC and normal intercalated cells
    description: >-
      Determine whether the chromosome losses arise in a single catastrophic
      mis-segregation event or accumulate sequentially, and whether normal or
      premalignant intercalated cells show any baseline segregation fragility.
  - experiment_id: exp_chrcc_proteostasis_profiling_aneuploidy
    name: Proteostasis profiling of aneuploid chRCC cells
    description: >-
      Test whether chRCC cells show the proteotoxic stress response expected of
      highly aneuploid cells, or have adapted a tolerance mechanism.
- discussion_id: chrcc_hypodiploidy_versus_gains
  prompt: >-
    Is the hypodiploid model of chromophobe renal cell carcinoma still accurate,
    given that later studies have documented frequent chromosomal gains
    alongside the classic loss pattern?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Recurrent Whole-Chromosome Loss
  - pathophysiology#Sarcomatoid Dedifferentiation
  rationale: >-
    The long-standing description of chRCC as a hypodiploid tumor comes from
    comparative genomic hybridization studies of the 1990s. Higher-resolution
    methods have since shown a more complex and heterogeneous picture in which
    chromosomal gains are also frequent, and gains are specifically associated
    with sarcomatoid tumors and with metastatic progression through imbalanced
    chromosome duplication. Whether hypodiploidy remains the right summary of
    chRCC genomics, or is better treated as the baseline state on which
    later gains are superimposed during progression, is unsettled and matters
    for how the diagnostic copy-number test is interpreted in aggressive tumors.
  evidence:
  - reference: PMID:33021507
    reference_title: "Comprehensive Review of Numerical Chromosomal Aberrations in Chromophobe Renal Cell Carcinoma Including Its Variant Morphologies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "It was thought for many years that ChRCC exhibits a hypodiploid genome. Recent studies using advanced molecular genetics techniques have shown more complex and heterogenous pattern with frequent chromosomal gains."
    explanation: >-
      Directly states the revision of the hypodiploid model that this discussion
      records as unsettled.
- discussion_id: chrcc_mtdna_driver_or_passenger
  prompt: >-
    Are the somatic mitochondrial DNA mutations found in most chromophobe renal
    cell carcinomas drivers of the tumor's oxidative phenotype, or passengers of
    its mitochondria-rich cell of origin?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Mitochondrial Accumulation and Oxidative Metabolic Phenotype
  rationale: >-
    Somatic mtDNA mutations, including frameshifting changes in complex I
    subunit genes, are present in the majority of chRCCs, and the tumor shows
    the highest mitochondrial gene expression among RCC subtypes. But the
    intercalated cell of origin is itself mitochondria-rich, so an oxidative
    phenotype is the expected inheritance rather than necessarily an acquired
    one. The original sequencing study explicitly declined to assign a causal
    role. Resolving this matters therapeutically, because targeting
    mitochondrial metabolism has been proposed as a chRCC-specific vulnerability
    and that proposal presumes a driver role.
  evidence:
  - reference: PMID:12353267
    reference_title: "Somatic mitochondrial DNA mutations in human chromophobe renal cell carcinomas."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Although somatic mtDNA mutations are found in chromophobe RCCs, their role in the maintenance of tumor cell phenotype or in tumorigenesis remains to be elucidated."
    explanation: >-
      The source study states the open question directly, which is what this
      discussion records.
disease_term:
  preferred_term: chromophobe renal cell carcinoma
  term:
    id: MONDO:0017885
    label: chromophobe renal cell carcinoma
classifications:
  icdo_morphology:
    classification_value: Carcinoma
  harrisons_chapter:
  - classification_value: ONCOLOGY_HEMATOLOGY
datasets:
- accession: geo:GSE20376
  title: Gene expression and SNP profiling discriminates chromophobe renal cell carcinoma and oncocytoma
  data_type: MICROARRAY
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  sample_count: 28
  notes: >-
    GEO series matched because chromophobe renal cell carcinoma is named in the
    dataset's own title. The SNP-profiling arm is the copy-number evidence
    underlying the characteristic monosomy pattern curated on the Recurrent
    Whole-Chromosome Loss node, and the paired oncocytoma samples are the
    comparator that makes the loss signature diagnostically useful. Relevance
    confirmed manually against the curated mechanism; retrieved 2026-08-15.
- accession: geo:GSE140390
  title: "Detection of tetraploidization in chromophobe renal cell carcinoma: insights and pitfalls [Affymetrix OncoScan_CNV]"
  data_type: MICROARRAY
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  sample_count: 25
  notes: >-
    GEO series matched because chromophobe renal cell carcinoma is named in the
    dataset's own title. Directly relevant to the open question recorded in the
    chrcc_hypodiploidy_versus_gains discussion, since it addresses genome
    doubling on top of the baseline loss pattern. Relevance confirmed manually;
    retrieved 2026-08-15.
- accession: geo:GSE52641
  title: Genomic profiling of chromophobe renal cell carcinoma by array-based comparative genomic hybridization
  data_type: MICROARRAY
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  sample_count: 4
  notes: >-
    GEO series matched because chromophobe renal cell carcinoma is named in the
    dataset's own title. Array CGH copy-number profiling, the method class that
    established the chromosome-loss signature. Small series (n=4). Relevance
    confirmed manually; retrieved 2026-08-15.
- accession: geo:GSE19982
  title: Gene expression discriminates chromophobe renal cell carcinoma and oncocytoma
  data_type: MICROARRAY
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  sample_count: 30
  publication: PMID:20462447
  notes: >-
    GEO series matched because chromophobe renal cell carcinoma is named in the
    dataset's own title. Expression-based separation of chRCC from its principal
    benign mimic, oncocytoma - the diagnostic problem curated on the
    eosinophilic subtype and the CD117/CK7 immunoprofile finding. Relevance
    confirmed manually; retrieved 2026-08-15.
- accession: geo:GSE224415
  title: "RBPJ::ALK : a novel fusion gene amplified in a metastatic sarcomatoid chromophobe renal cell carcinoma"
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  sample_count: 3
  notes: >-
    GEO series matched because sarcomatoid chromophobe renal cell carcinoma is
    named in the dataset's own title. Relevant to the Sarcomatoid
    Dedifferentiation and Metastatic Dissemination nodes. Single-case series
    (n=3), so it illustrates rather than establishes the sarcomatoid genomic
    profile. Relevance confirmed manually; retrieved 2026-08-15.
references:
- reference: PMID:20301695
  title: "Birt-Hogg-Dubé Syndrome."
  tags:
  - GeneReviews
notes: >-
  GeneReviews baseline: no GeneReviews chapter exists for chromophobe renal cell
  carcinoma itself, which is a somatically driven tumor entity rather than a
  Mendelian disorder. The Birt-Hogg-Dube Syndrome chapter (PMID:20301695) is the
  relevant GeneReviews source for the hereditary FLCN-mediated predisposition and
  is cited on the FLCN genetic entry and tagged in the top-level references block.
📚

References & Deep Research

References

1
PMID:20301695
Birt-Hogg-Dubé Syndrome.
No top-level findings curated for this source.

Deep Research

1
Claude Code ▸
Chromophobe Renal Cell Carcinoma (ChRCC): Comprehensive Research Report
claude-haiku-4-5-20251001, claude-sonnet-5 37 citations 2026-08-15T01:54:05.539608

Chromophobe Renal Cell Carcinoma (ChRCC): Comprehensive Research Report

1. Disease Information

Overview

Chromophobe renal cell carcinoma (ChRCC) is a distinct malignant epithelial neoplasm of the kidney, believed to arise from the intercalated cells of the distal nephron/collecting duct (in contrast to clear cell RCC, which arises from proximal tubule cells) (PMID:25155756). It is the third most common renal cell carcinoma subtype after clear cell RCC (ccRCC) and papillary RCC, accounting for approximately 5–7% (range 5–10%) of all RCC cases. It is characterized histologically by large polygonal cells with prominent cell membranes, finely reticulated ("wispy") pale cytoplasm, perinuclear halos, and raisinoid (wrinkled) nuclei, and molecularly by a distinctive pattern of multiple whole-chromosome losses and a comparatively low point-mutation burden. ChRCC is generally regarded as a tumor of relatively low malignant potential with favorable prognosis compared with clear cell and most papillary RCCs, though a subset — particularly tumors with sarcomatoid dedifferentiation — behaves aggressively.

Key Identifiers

  • MONDO ID: MONDO:0017885
  • Orphanet ID: ORPHA:319303
  • ICD-11: XH6153 (Renal cell carcinoma, chromophobe type); parent code 2C90 (Malignant neoplasms of kidney, except renal pelvis)
  • ICD-O-3 morphology code: 8270/3
  • OMIM: No disease-specific OMIM entry exists for sporadic ChRCC; it falls under the general nonpapillary renal cell carcinoma entry OMIM #144700. Birt–Hogg–Dubé syndrome (the principal hereditary predisposition syndrome) is OMIM #135150 (FLCN gene, OMIM 607273).
  • MeSH: Carcinoma, Renal Cell (D002292); no distinct MeSH heading for the chromophobe subtype specifically, indexed under this parent term.

Synonyms

Chromophobe adenocarcinoma of kidney; chromophobe carcinoma of kidney; chromophobe cell carcinoma of kidney; chromophobe cell renal carcinoma; chromophobe renal cell adenocarcinoma; ChRCC (common abbreviation).

Data Source Character

Information on ChRCC is derived predominantly from aggregated disease-level resources: multi-institutional surgical pathology case series (e.g., 145-case and 53-case cohorts), national cancer registries (SEER), and large consortium genomic studies (The Cancer Genome Atlas [TCGA] KICH cohort, n=66) (PMID:25155756; PMID:18813125). Individual-patient-level EHR data are less commonly published given the tumor's rarity; most clinical outcome data come from retrospective institutional or registry-based cohorts rather than prospective clinical trials specific to this histology, reflecting the broader challenge of studying rare RCC subtypes.

2. Etiology

Disease Causal Factors

The great majority (~95%+) of ChRCC cases are sporadic, arising from somatic (acquired) genomic events — principally large-scale chromosomal losses and, in a subset, TP53/PTEN pathway mutations and mitochondrial DNA (mtDNA) alterations (PMID:25155756). A minority of cases occur in the context of hereditary tumor-predisposition syndromes, most notably Birt–Hogg–Dubé (BHD) syndrome, in which ChRCC (and the closely related hybrid oncocytic/chromophobe tumor, HOCT) is the dominant renal tumor histology.

Genetic Risk Factors

Birt–Hogg–Dubé syndrome (FLCN, OMIM 607273, chr17p11.2). Autosomal dominant loss-of-function mutations in the folliculin (FLCN) tumor suppressor gene cause BHD syndrome, characterized by fibrofolliculomas, pulmonary cysts/spontaneous pneumothorax, and multiple, often bilateral, renal tumors — most commonly hybrid oncocytic/chromophobe tumors and chromophobe RCC, followed by clear cell and papillary histologies (PMID:36258004). Comparative genomic studies show BHD-associated ChRCC/HOCT is molecularly distinct from sporadic ChRCC, lacking the characteristic sporadic-ChRCC chromosome-loss signature and instead showing FLCN biallelic inactivation with mTORC1 pathway hyperactivation (PMC10200853).

Cowden syndrome / PTEN hamartoma tumor syndrome (PTEN, OMIM 601728). Germline PTEN mutations confer elevated lifetime risk of renal cell carcinoma (in addition to breast, thyroid, and endometrial cancer), with RCC risk estimated in some cohorts to approach 15–34% lifetime; ChRCC is one of the reported histologies. Somatically, PTEN is also the second most frequently mutated gene in sporadic ChRCC (~9% of TCGA cases) (PMID:25155756), converging genetic evidence on PTEN/mTOR pathway dysregulation as a recurring driver axis.

Tuberous sclerosis complex (TSC1/TSC2, OMIM #191100/#613254) and germline succinate dehydrogenase (SDH) mutations are associated with distinct renal tumor entities (angiomyolipoma/eosinophilic solid-and-cystic RCC for TSC; SDH-deficient RCC for SDHB/SDHC/SDHD) that enter the differential diagnosis of, and occasionally overlap morphologically with, chromophobe/oncocytic tumors, though these are separate WHO entities rather than ChRCC itself.

Somatic driver landscape (TCGA, n=66 tumors) (PMID:25155756): - TP53 — most frequently mutated gene, ~32% of cases; mutations correlate with decreased expression of p53 transcriptional targets and are enriched in the more aggressive "eosinophilic"/high-grade subset. - PTEN — ~9% of cases (nonsilent mutations). - mTOR pathway — mutations in MTOR, NRAS, TSC1, and TSC2 collectively occur in ~23% of cases, converging on mTORC1 hyperactivation as a major pathway. - TERT promoter structural rearrangements — recurrent structural breakpoints juxtapose the TERT promoter with strong enhancers, correlating with markedly elevated TERT expression and localized hypermutation ("kataegis") — a mechanism of telomerase reactivation distinct from the point mutations/amplifications seen in other cancers. - ~40% of tumors have no identified driver mutation in a known oncogene/tumor suppressor, implicating the characteristic chromosomal-loss pattern itself (see Genetic/Molecular section) as a primary oncogenic event.

Environmental Risk Factors

No environmental exposure has been specifically and robustly linked to ChRCC as distinct from RCC broadly. General RCC risk factors — cigarette smoking, obesity, hypertension, acquired cystic kidney disease in dialysis patients, and occupational exposure to trichloroethylene — apply to renal cancer as a class; ChRCC-specific epidemiologic data isolating these exposures are limited given the tumor's rarity.

Protective Factors

No specific genetic or environmental protective factors have been established for ChRCC; general RCC-protective associations (e.g., physical activity, moderate alcohol intake) reported in broader RCC epidemiology have not been separately validated for the chromophobe subtype.

Gene-Environment Interactions

Not well characterized for ChRCC specifically; the tumor's genomic architecture (whole-chromosome loss plus a low point-mutation burden) suggests a less environmentally mutagen-driven pathogenesis than smoking-associated urothelial or some clear-cell RCC cases, consistent with its occurrence at a somewhat younger mean age and with strong intrinsic genomic instability as the dominant driver mechanism.

3. Phenotypes

Because ChRCC is a solid tumor, its "phenotypes" are principally clinical presenting features, laboratory/imaging findings, and pathologic characteristics rather than a syndromic multi-organ phenotype (except in the context of BHD syndrome, discussed above).

Clinical Signs and Symptoms

  • Often asymptomatic, incidentally discovered on imaging performed for unrelated indications — an increasingly common presentation pattern for renal masses generally.
  • Flank pain — HPO: HP:0030057 (Flank pain)
  • Hematuria — HPO: HP:0000790 (Hematuria)
  • Palpable abdominal/flank mass — HPO: HP:0031817 (Abdominal mass) / HP:0031279 (Renal mass, if available) — a palpable renal mass, when present with pain and hematuria, forms the classic (but now uncommon) triad seen more with advanced-stage disease.
  • Weight loss — HPO: HP:0001824
  • Fatigue — HPO: HP:0012378

Phenotype Characteristics

  • Age of onset: Adult-onset; mean age at diagnosis ~59 years (range 27–82 in the largest surgical series) (PMID:18813125); somewhat younger on average than clear cell RCC.
  • Severity/progression: Most tumors behave indolently (low-grade, low metastatic potential); a minority show aggressive behavior, particularly with sarcomatoid or rhabdoid dedifferentiation, high nuclear grade, or the eosinophilic morphologic variant, which — despite resembling benign oncocytoma — can behave more aggressively than classic ChRCC.
  • Multifocality/bilaterality: Present in ~8% and ~3% of cases respectively in sporadic disease (PMID:18813125); bilaterality and multifocality are much more common in BHD-associated disease and should prompt genetic evaluation.
  • Tumor size at diagnosis: Frequently large; mean ~8.0 cm (range 1.0–30.0 cm) in surgical series, often larger than clear cell RCC at diagnosis despite favorable behavior (PMID:18813125).

Imaging Findings (a major "phenotype" category for renal masses)

  • Homogeneous, well-circumscribed solid renal mass, often hypovascular relative to clear cell RCC.
  • Central stellate scar with "spoke-wheel"-pattern enhancement on contrast CT/MRI — reported in a substantial minority of cases (historically ~27% in early case series) and classically associated with (but not specific for, and overlapping with) oncocytoma (PMID:15479284).
  • Segmental enhancement inversion on multiphase MRI has been proposed as a discriminating feature between ChRCC and oncocytoma, though sensitivity is limited (reported in only a small percentage of cases in some series).

Frequency Among Affected Individuals

Because ChRCC is itself the "disease" rather than a phenotype-bearing syndrome, formal HPO frequency annotation of individual signs (e.g., "flank pain in X% of ChRCC patients") is less standardized than for Mendelian disease; most series report the majority of cases as incidentally discovered, with symptomatic presentation (pain, hematuria, mass) more typical of larger or locally advanced tumors.

Quality of Life Impact

Localized, surgically resected ChRCC generally carries minimal long-term QoL impact beyond standard post-nephrectomy renal function considerations. Metastatic disease carries QoL burdens similar to other advanced RCCs, including treatment-related toxicity from targeted/immunotherapy agents (fatigue, hand-foot syndrome with TKIs, immune-related adverse events with checkpoint inhibitors such as colitis and interstitial nephritis) (academic.oup.com/oncolo/29/5/392).

4. Genetic/Molecular Information

Causal/Driver Genes

No single gene is causally sufficient for sporadic ChRCC in the way, e.g., VHL is for clear cell RCC. Instead, ChRCC is defined by a characteristic multi-chromosome loss signature plus a low but recurrent point-mutation burden in TP53 and PTEN (PMID:25155756).

Chromosomal Abnormalities — the defining molecular signature

A hallmark, near-pathognomonic feature: combined monosomy/loss of chromosomes 1, 2, 6, 10, 13, 17, and 21, occurring in 70–93% of cases, first described by comparative genomic hybridization (PMID:7519827) and confirmed by TCGA (loss of most/all of chromosomes 1, 2, 6, 10, 13, and 17 in 86% of cases) (PMID:25155756). Karyotypically, tumors frequently show a markedly hypodiploid chromosome count (32–39), sometimes with subsequent endoreduplication producing a near-diploid or hyperdiploid appearance. This combination of losses is used diagnostically to distinguish ChRCC from renal oncocytoma and other mimics, and the classic morphologic variant loses significantly more chromosomes than the eosinophilic variant (PMID:33021507).

Pathogenic Variants

  • TP53 (HGNC:11998; chr17p13.1) — ~32% of TCGA cases; missense and truncating mutations; somatic. Associated with worse outcome and enrichment in high-grade/eosinophilic tumors.
  • PTEN (HGNC:9588; chr10q23.31) — ~9% of cases; somatic loss-of-function; converges with germline PTEN (Cowden syndrome) and FLCN (BHD) pathways on mTORC1 hyperactivation as a recurring pathogenic mechanism.
  • MTOR, NRAS, TSC1, TSC2 — collectively mutated in ~23% of cases (PMID:25155756), reinforcing mTOR pathway centrality; a Modern Pathology molecular study found mTOR pathway alterations enriched in patients with poor outcome (S0893395222004264).
  • TERT promoter structural rearrangements — recurrent enhancer-hijacking breakpoints near the TERT promoter, correlating with elevated TERT expression and a localized hypermutation ("kataegis") signature — a distinctive telomerase-reactivation mechanism (PMID:25155756).
  • FLCN (HGNC:27310; chr17p11.2) — germline biallelic loss in BHD-associated tumors (not typically somatically mutated in sporadic ChRCC).
  • Mitochondrial DNA (mtDNA) mutations — somatic mtDNA mutations, particularly in genes encoding NADH dehydrogenase (Complex I) subunits, have been reported in ChRCC since early sequencing studies (PMID:12353267). A specific C3572ins insertion in MT-ND1 has been reported in the eosinophilic variant, potentially disrupting Complex I structure/function; ND1 mutations are associated with worse 5-year recurrence-free survival in localized RCC generally (PMID:5187849/PMC5187849). TCGA analysis found ChRCC shows the highest expression of 13 mtDNA-encoded genes among RCC subtypes and increased mitochondrial genome content, with near-universal upregulation of Krebs cycle and electron transport chain (ETC) genes relative to normal kidney (PMID:25155756).

Variant Classification / Allele Frequency

As a somatic cancer-driver context, variants are typically classified via COSMIC/cancer-specific frameworks (pathogenic somatic driver vs. passenger) rather than ACMG/AMP germline classification, except for the germline FLCN, PTEN, TSC1/2, and SDHx variants relevant to hereditary predisposition, which follow standard ClinVar/ACMG classification.

Somatic vs. Germline Origin

The overwhelming majority of ChRCC-associated variants (TP53, PTEN, MTOR pathway, TERT rearrangements, mtDNA mutations, chromosomal losses) are somatic. Germline variants (FLCN in BHD, PTEN in Cowden syndrome) account for the hereditary minority and are associated with characteristic multifocal/bilateral, earlier-onset, hybrid-histology disease.

Functional Consequences

  • TP53 loss-of-function → impaired p53-dependent transcriptional responses (apoptosis, senescence, DNA damage response).
  • PTEN loss / MTOR-TSC1/TSC2-NRAS alterations → constitutive mTORC1 pathway activation, driving anabolic growth signaling — the mechanistic rationale for mTOR-inhibitor (everolimus) sensitivity in metastatic disease.
  • TERT promoter rearrangement → gain-of-function-like transcriptional upregulation of telomerase, promoting replicative immortality.
  • Complex I mtDNA mutations → altered oxidative phosphorylation efficiency and mitochondrial oxidative stress, proposed as a partially independent (from mTOR) oncogenic axis specific to this tumor's distal-nephron, mitochondria-rich cell of origin (S1040842825003737; PMID:25155756).

Modifier Genes

CDKN1A (p21) loss of mRNA/protein expression has been identified as an independent predictor of poor outcome in ChRCC (PMC7072616), suggesting a modifying role for cell-cycle checkpoint regulators beyond the core driver genes.

Epigenetic Information

TCGA multi-platform analysis included DNA methylation profiling of ChRCC as part of its integrated molecular characterization; ChRCC shows a distinctive expression/methylation profile relative to other RCC subtypes consistent with its distal-nephron/intercalated-cell origin, though disease-specific therapeutic epigenetic targets remain an active research area (S1040842825003737, "emerging vulnerabilities").

Suggested ontology terms: HGNC:11998 (TP53), HGNC:9588 (PTEN), HGNC:27310 (FLCN), HGNC:3942 (TSC1), HGNC:12363 (TSC2), HGNC:3942/HGNC:12395 (MTOR), HGNC:1791 (CDKN1A); GO:0031929 (TOR signaling), GO:0006457 (protein folding — not central here), GO:0006120 (mitochondrial electron transport, NADH to ubiquinone).

5. Environmental Information

Environmental Factors

No disease-specific environmental toxin has been robustly and specifically associated with ChRCC (as distinct from RCC as a whole). General renal carcinogen exposures (trichloroethylene, cadmium, certain herbicides) are studied predominantly in relation to clear cell RCC.

Lifestyle Factors

Smoking and obesity are established general RCC risk factors; ChRCC-specific attributable-risk data are sparse given the tumor's rarity and the difficulty of subtype-stratified epidemiologic studies.

Infectious Agents

Not applicable — ChRCC has no established infectious etiology.

6. Mechanism / Pathophysiology

Causal Chain Overview

ChRCC pathogenesis centers on a convergence of (1) large-scale genomic instability producing the characteristic multi-chromosome loss pattern, (2) recurrent point mutations/pathway alterations converging on mTORC1 hyperactivation (via PTEN, MTOR, TSC1/2, NRAS, or germline FLCN loss), and (3) mitochondrial dysfunction with altered oxidative phosphorylation, reflecting the tumor's origin from mitochondria-rich distal nephron intercalated cells.

Upstream events: - Whole-chromosome losses (1, 2, 6, 10, 13, 17, 21) — an early, near-universal genomic event of unclear precise mechanism, possibly reflecting a distinct chromosomal instability process in the cell of origin. - TERT promoter structural rearrangement — enables replicative immortality.

Midstream/convergent pathway alterations: - PTEN loss / TSC1-TSC2-MTOR-NRAS mutations / germline FLCN loss → loss of negative regulation of mTORC1 → increased protein synthesis, cell growth, and proliferation (GO:0031929, TOR signaling; GO:0038202, TORC1 signaling). - TP53 mutation → impaired DNA damage response/apoptosis, permitting accumulation of further genomic instability; enriched in higher-grade, more aggressive tumors.

Downstream/metabolic consequences: - Increased mitochondrial genome content and near-universal transcriptional upregulation of Krebs cycle and electron transport chain (ETC) genes relative to normal kidney — a metabolic reprogramming distinct from the glycolytic (Warburg) shift typical of clear cell RCC, consistent with ChRCC retaining an oxidative-phosphorylation-dependent metabolic phenotype (PMID:25155756). - Somatic mtDNA mutations (notably in Complex I/ND subunits) may further perturb ETC function and increase oxidative stress, potentially contributing to genomic instability and influencing prognosis (recurrence-free survival) (PMID:5187849).

Cellular Processes

  • Cell cycle dysregulation (via TP53/CDKN1A axis)
  • Anabolic growth signaling (mTORC1 pathway) — GO:0016239 not directly, but GO:0045821 (positive regulation of glycolytic process) is more relevant to ccRCC; for ChRCC the relevant term is oxidative-phosphorylation maintenance, GO:0006119 (oxidative phosphorylation).
  • Impaired apoptosis/DNA damage response (TP53-dependent) — GO:0006977 (DNA damage response, signal transduction by p53).
  • Telomere maintenance (TERT reactivation) — GO:0007004 (telomere maintenance via telomerase).

Protein Dysfunction

  • p53: loss of transcriptional activator function (many mutations are missense, disrupting DNA-binding domain function, consistent with dominant-negative or loss-of-function effects typical of TP53 cancer mutations).
  • PTEN: loss of lipid phosphatase activity (PIP3 → PIP2 dephosphorylation), removing the brake on PI3K-AKT-mTOR signaling.
  • Mitochondrial Complex I subunits (e.g., ND1): structural/functional impairment from mtDNA insertions/mutations, potentially reducing ETC efficiency.

Metabolic Changes

Distinctive oxidative, mitochondria-centered metabolic phenotype (elevated ETC and Krebs cycle gene expression, increased mtDNA copy number), contrasting with the glycolytic/pseudohypoxic phenotype of VHL-mutant clear cell RCC — an important conceptual distinction, since it implies ChRCC tumor cells may remain relatively dependent on oxidative phosphorylation, a potential therapeutic vulnerability under active investigation (S1040842825003737).

Tissue Damage / Cell of Origin

Immunohistochemical, ultrastructural, and TCGA transcriptomic evidence supports origin from intercalated cells of the distal nephron/cortical collecting duct, distinguishing ChRCC from clear cell RCC (proximal tubule origin) and explaining shared antigenic overlap with the benign oncocytoma (also thought to arise from intercalated cells), which underlies their diagnostic overlap.

Molecular Profiling Summary (TCGA KICH, n=66) (PMID:25155756)

  • Transcriptomics: Distal-nephron gene expression signature; upregulation of mitochondrial/OXPHOS genes.
  • Genomics: Low somatic mutation rate overall; dominant signal is arm/whole-chromosome copy-number loss rather than point mutation burden.
  • mtDNA sequencing: Recurrent somatic mtDNA mutations, particularly Complex I genes.
  • Structural variation: TERT promoter rearrangements as a recurrent, disease-defining structural event.

Single-Cell / Spatial / Multi-omics

Dedicated single-cell and spatial transcriptomic atlases of ChRCC are less mature than for clear cell RCC given rarity, but emerging work (e.g., studies of the hybrid oncocytic/chromophobe tumor in BHD syndrome) uses sequencing to resolve dual lineage markers capturing the two cellular populations of HOT, distinguishing oncocytoma-like and chromophobe-like cell populations within hybrid tumors (PMC10871670).

7. Anatomical Structures Affected

Organ Level

  • Primary organ: Kidney (UBERON:0002113), specifically arising in the renal cortex from the distal nephron/collecting duct system.
  • Secondary/metastatic sites (in advanced disease): lung, liver, bone, and regional lymph nodes — a pattern broadly similar to other RCC subtypes, though metastatic ChRCC is less common than in clear cell RCC given its generally indolent behavior.
  • Body systems: Genitourinary system primarily; renal insufficiency can occur post-nephrectomy or with bilateral disease (as in BHD syndrome).

Tissue and Cell Level

  • Tissue type: Renal epithelial (glandular) tissue.
  • Cell of origin / cell type involved: Intercalated cells of the distal nephron/cortical collecting duct — Cell Ontology candidate term CL:1000497 (kidney collecting duct intercalated cell) or more specifically CL:0002201 (collecting duct intercalated cell).
  • Tumor cells themselves: large, polygonal cells with abundant pale reticulated cytoplasm ("plant-cell" appearance) and prominent cell membranes.

Subcellular Level

  • Mitochondria (GO:0005739, mitochondrion) — central to pathophysiology; tumor cells are characteristically packed with mitochondria (contributing to the "chromophobe" — pale, poorly staining — cytoplasmic appearance on light microscopy, related to microvesicle accumulation rather than mitochondrial density per se, though mitochondrial content is elevated at the molecular level per TCGA data).
  • Cytoplasmic microvesicles (ultrastructurally distinctive, contributing to the finely reticulated cytoplasmic texture).
  • Nucleus — irregular, wrinkled ("raisinoid") nuclear contour, a key diagnostic feature.

Localization

  • Renal mass, typically unifocal in sporadic disease; UBERON:0002113 (kidney), more specifically involving the renal parenchyma/cortex.
  • Lateralization: Usually unilateral in sporadic disease; bilaterality (~3% sporadic) is a hallmark clue to BHD syndrome when present, and multifocality within one kidney occurs in ~8% (PMID:18813125).

8. Temporal Development

Onset

  • Adult-onset malignancy; mean age at diagnosis ~59 years (range 27–82) (PMID:18813125); some sources note diagnoses clustering in the 40–50 age range as well, reflecting heterogeneity across cohorts, with overall a somewhat younger mean age than clear cell RCC.
  • Onset pattern: Typically insidious — an asymptomatic mass discovered incidentally on imaging performed for unrelated reasons, reflecting the generally indolent natural history.

Progression

  • Disease stages: Staged using the standard AJCC/TNM system for renal cell carcinoma (pT1–pT4, N, M), the same staging framework applied across RCC histologic subtypes; ChRCC-specific prognostic nomograms (Leibovich 2018, GRANT models) have also been developed and externally validated using SEER data (PMC10093654).
  • Progression rate: Generally slow/indolent for classic ChRCC; more rapid and aggressive when sarcomatoid/rhabdoid dedifferentiation, high nuclear grade, or the eosinophilic variant is present.
  • Disease course pattern: Typically stable/slowly progressive if untreated over years in localized disease; can recur or metastasize years after nephrectomy in a minority of cases, warranting long-term surveillance.
  • Duration: Curable with surgery in the majority of localized cases; chronic/incurable in the metastatic setting, though median survival even then is measured in years for many patients given the generally favorable underlying biology, in contrast to more rapidly fatal metastatic clear cell RCC.

Patterns

  • Remission: Surgical resection (partial or radical nephrectomy) is curative in the vast majority of localized cases; no established spontaneous remission pattern.
  • Critical periods: Early detection via incidental imaging is the primary driver of favorable outcomes; delayed diagnosis with larger tumor size or dedifferentiated (sarcomatoid) transformation is associated with worse prognosis, making surveillance imaging in known predisposition syndromes (e.g., BHD) clinically important for early intervention.

9. Inheritance and Population

Epidemiology

  • Prevalence/proportion of RCC: ChRCC accounts for approximately 5–7% (range cited 5–10%) of all renal cell carcinomas.
  • Incidence: Estimated annual age-standardized incidence in Western populations of roughly 0.5–1 per 100,000 individuals.

Inheritance Pattern (for hereditary forms)

  • Birt–Hogg–Dubé syndrome: Autosomal dominant (FLCN, OMIM #135150); high but incomplete penetrance for cutaneous and pulmonary manifestations, with variable renal tumor risk (lifetime renal tumor risk estimated around 15–30% in various cohorts, though estimates vary).
  • Cowden syndrome (PTEN hamartoma tumor syndrome): Autosomal dominant (PTEN, OMIM #158350); variable expressivity across the classic Cowden phenotypic spectrum, with RCC (including ChRCC) as one of several associated malignancies alongside breast, thyroid, and endometrial cancer.
  • Sporadic ChRCC itself, being a somatically driven malignancy, has no Mendelian inheritance pattern.

Penetrance / Expressivity

BHD-associated renal tumor risk is age-dependent and incompletely penetrant; expressivity is variable even within families (histology mix of ChRCC, HOCT, oncocytoma, clear cell, and papillary tumors can differ between affected relatives).

Founder Effects / Consanguinity

Not specifically documented for ChRCC or its associated syndromes; FLCN and PTEN pathogenic variants occur across diverse populations without a strong reported founder-population enrichment specific to renal manifestations.

Population Demographics

  • Sex ratio: Reported as roughly male:female 1.1:1 in the largest histomorphologic series (PMID:18813125), though other summary sources describe a slight female predominance — the literature is not fully concordant, and sex distribution appears closer to balanced than the male predominance seen in clear cell RCC.
  • Geographic distribution: No strong endemic geographic clustering reported; distribution roughly parallels general RCC incidence patterns globally, modulated by imaging utilization rates (higher incidental detection in high-resource settings with frequent cross-sectional imaging).
  • Age distribution: Peak diagnosis in the 5th–6th decade of life; can occur across a wide age range (documented from late 20s to 80s) (PMID:18813125).

10. Diagnostics

Clinical/Laboratory Tests

  • Routine urinalysis (hematuria assessment), basic metabolic panel/renal function testing — nonspecific, used in general renal mass workup rather than ChRCC-specific diagnosis.
  • No validated blood or urine biomarker is specific for ChRCC at present.

Imaging Studies

  • Contrast-enhanced CT — first-line for renal mass characterization; ChRCC typically appears as a well-circumscribed, homogeneously enhancing (often less avidly than clear cell RCC) solid mass, sometimes with a central stellate scar and "spoke-wheel" enhancement pattern (PMID:15479284).
  • MRI — used particularly to assess segmental enhancement inversion, a proposed (though imperfectly sensitive) discriminator from oncocytoma (PMC11992432).
  • Multiphase MDCT enhancement pattern analysis has been studied to differentiate ChRCC from other renal masses (AJR.13.10813).

Biopsy / Pathology (definitive diagnosis)

  • Renal mass core-needle biopsy or nephrectomy specimen — gold standard for diagnosis.
  • Histopathology: Large polygonal cells with pale, finely reticulated ("wispy") cytoplasm, sharp/distinct ("plant-cell-like") cell membranes, perinuclear halos, and irregular ("raisinoid") nuclear contours; classic vs. eosinophilic morphologic variants recognized.
  • Special stains: Hale's colloidal iron stain classically shows diffuse cytoplasmic staining in ChRCC (though now used less due to variable/focal staining and superseded largely by immunohistochemistry) (pathologyoutlines.com).
  • Immunohistochemistry — the "three 7" panel: CK7 (positive, diffusely in >75% of cases), CD117/KIT (positive in ~95.5% of cases), and Claudin-7 — combined use is highly effective for confirming ChRCC and excluding mimics such as oncocytoma (typically CK7-focal/negative) and clear cell RCC (typically CD117-negative) (PMC6815563).
  • Electron microscopy: Characteristic numerous cytoplasmic microvesicles, historically used to confirm diagnosis in ambiguous cases (PMC4687210).

Genetic Testing

  • Not routinely required for sporadic ChRCC diagnosis (which is a histopathologic/immunohistochemical diagnosis), but germline FLCN testing should be considered in patients with bilateral/multifocal tumors, hybrid oncocytic/chromophobe histology, young age at diagnosis, or a personal/family history suggestive of BHD syndrome (fibrofolliculomas, spontaneous pneumothorax). Germline PTEN testing is indicated when Cowden syndrome features are present.
  • Cytogenetic/FISH or copy-number array testing for the characteristic multi-chromosome loss pattern (chromosomes 1, 2, 6, 10, 13, 17, 21) can support diagnosis in histologically ambiguous cases, distinguishing ChRCC from oncocytoma and other mimics.

Differential Diagnosis

  • Renal oncocytoma — the principal benign mimic; distinguished by more diffuse/uniform CK7-negative or focal staining, absence of the characteristic chromosomal loss pattern, and different nuclear features (though "hybrid oncocytic/chromophobe tumor" represents genuine morphologic overlap, especially in BHD syndrome).
  • Eosinophilic solid and cystic RCC (ESC-RCC) — a distinct WHO 2022-recognized entity, sometimes TSC1/TSC2-mutated, in the differential for oncocytic renal tumors.
  • Low-grade oncocytic tumor (LOT) — an emerging provisional entity in the WHO 2022 classification, overlapping morphologically with both oncocytoma and eosinophilic ChRCC.
  • Succinate dehydrogenase (SDH)-deficient RCC and clear cell RCC (eosinophilic variants) — distinguished by SDHB immunohistochemistry loss and CA-IX/CD10 positivity respectively.

Screening

No population-level screening program exists for sporadic ChRCC given its rarity and generally favorable prognosis. In confirmed BHD syndrome, periodic renal imaging surveillance (e.g., MRI every 1–3 years starting in early adulthood) is recommended given the risk of multiple, recurrent renal tumors.

11. Outcome/Prognosis

Survival and Mortality

ChRCC has a notably favorable prognosis relative to other RCC subtypes: - 5-year overall survival: Reported around 91% in aggregate literature, with SEER-based analyses showing 5-year overall survival for localized, post-nephrectomy disease exceeding 95%, and cancer-specific survival approaching 98%. - 5-year and 10-year cancer-specific survival (broader literature range): 78–100% and 80–90% respectively, reflecting biological behavior of "low malignant potential" for the majority of tumors. - Metastatic disease: Median overall survival is more guarded, approximately 24 months in the targeted-therapy era, underscoring the divergent prognosis between localized and advanced disease.

Prognostic Models

The Leibovich 2018 and GRANT (Grade, Age, Nodes, Tumor) models have been externally validated specifically for non-metastatic ChRCC using a SEER cohort of 5,522 patients, showing moderate discriminative accuracy (concordance ~0.64–0.65 at 10 years) — indicating room for improvement in ChRCC-specific prognostic tools relative to their performance in clear cell RCC (PMC10093654). SEER-based nomograms for overall and cancer-specific survival have also been developed (PMC9438212).

Morbidity and Function

Post-nephrectomy renal function considerations are relevant, particularly with bilateral/multifocal disease (as in BHD syndrome) where nephron-sparing (partial nephrectomy) approaches are prioritized to preserve function across repeated interventions.

Disease Course / Complications

  • Sarcomatoid and/or rhabdoid dedifferentiation is the principal adverse prognostic feature, associated with markedly worse survival and a shift toward more aggressive, systemic-therapy-requiring disease.
  • Loss of CDKN1A (p21) mRNA/protein expression is an independent predictor of poor outcome (PMC7072616).
  • TP53 mutation and mTOR pathway alterations are associated with poorer outcomes in molecular characterization studies (S0893395222004264).
  • MT-ND1 (mitochondrial Complex I) mutation status has been associated with worse recurrence-free survival in localized RCC (PMC5187849).

Prognostic Factors/Biomarkers

Tumor stage (pT), nuclear grade, presence of sarcomatoid/rhabdoid features, TP53 mutation status, mTOR pathway alteration status, and CDKN1A expression loss are the principal reported prognostic correlates.

12. Treatment

Surgical (primary curative modality)

  • Partial nephrectomy (nephron-sparing surgery) — preferred when technically feasible, especially important in bilateral/multifocal disease (e.g., BHD syndrome) to preserve renal function across potential repeat surgeries.
  • Radical nephrectomy — for larger or anatomically unfavorable tumors.
  • NCIT suggested term: NCIT:C15329 (Surgical Procedure); more specifically partial/radical nephrectomy procedure codes.

Pharmacotherapy — Metastatic/Advanced Disease

  • mTOR inhibitors (everolimus) — mechanistically well-supported given the mTORC1 pathway centrality in ChRCC pathogenesis (via PTEN/TSC1/TSC2/MTOR mutations and FLCN loss in hereditary cases); the ASPEN phase II study reported a chromophobe RCC cohort progression-free survival of 11.4 months with everolimus, among the better-performing non-clear-cell RCC histologies in that trial.
  • NCIT: NCIT:C15986 (Pharmacotherapy); therapeutic_agent CHEBI term for everolimus (CHEBI:68478).
  • VEGFR tyrosine kinase inhibitors (sunitinib, cabozantinib, pazopanib) — used per general non-clear-cell RCC guidelines; case reports document exceptional responses of metastatic ChRCC to VEGF inhibitors, with increased VEGF-C expression proposed as a potential predictive biomarker in some cases (PMC6949673).
  • Combination regimens — current NCCN-guideline-informed approaches for advanced non-clear-cell RCC (including ChRCC) favor doublet therapy: VEGFR-inhibitor + mTOR-inhibitor, VEGFR-inhibitor + immune checkpoint inhibitor, or doublet checkpoint inhibition, extrapolated substantially from broader RCC trials given the paucity of ChRCC-specific randomized data.
  • Lenvatinib plus everolimus — evaluated in a phase 2 study for advanced non-clear-cell RCC including ChRCC (PMC12684810).
  • Pembrolizumab plus lenvatinib — under investigation in the first-line advanced/metastatic non-clear-cell RCC setting (KEYNOTE trial program, NCT04704219).

Immunotherapy

  • Immune checkpoint inhibitors (nivolumab, ipilimumab-nivolumab combination) — case reports document significant responses in metastatic ChRCC with sarcomatoid differentiation, including a notable case of response to nivolumab as seventh-line therapy (PMID:29558933/PMC5907256) and additional cases using combination checkpoint blockade as first-line therapy for sarcomatoid ChRCC (link.springer.com/10.1007/s13691-022-00561-y). Immune-related adverse events reported include interstitial nephritis and colitis.
  • NCIT term candidates: monoclonal antibody / immune checkpoint inhibitor class terms; therapeutic_modality: MONOCLONAL_ANTIBODY.

Treatment for Sarcomatoid/Rhabdoid Dedifferentiation

  • This aggressive subset is treated more like sarcomatoid RCC generally: combination immune checkpoint therapy is a preferred first-line approach; cabozantinib as second/third-line therapy after progression on VEGFR-TKI or checkpoint inhibitor combinations has shown objective response rates of 44–47% in retrospective multicenter series of sarcomatoid-dedifferentiated RCC (academic.oup.com/oncolo/29/5/392).

Surveillance/Active Monitoring

Active surveillance is a reasonable option for small, incidentally discovered renal masses in appropriately selected (e.g., elderly, comorbid) patients, given ChRCC's generally indolent behavior, though tissue diagnosis (biopsy) is typically pursued first given the differential with oncocytoma and other entities.

Experimental/Emerging

Given ChRCC's distinctive mitochondrial/oxidative phosphorylation-dependent metabolism, targeting mitochondrial vulnerabilities has been proposed as an emerging therapeutic strategy, reviewed as "emerging vulnerabilities" for a new therapeutic landscape in recent literature (S1040842825003737). HIF2α inhibitors (e.g., belzutifan) are primarily developed for VHL-pathway-driven clear cell RCC and are not a standard mechanistic fit for ChRCC, though broader RCC trials sometimes include mixed histology cohorts.

13. Prevention

Primary Prevention

No specific primary prevention strategy exists for sporadic ChRCC beyond general cancer risk-factor modification (smoking cessation, weight management) applicable to RCC broadly.

Secondary Prevention / Screening

  • In confirmed hereditary predisposition (BHD syndrome, Cowden syndrome), periodic renal imaging surveillance (typically MRI to limit cumulative radiation exposure given repeated lifetime studies) is recommended to enable early detection and nephron-sparing surgical management before tumors grow large or multiply.
  • Incidental detection via imaging performed for unrelated indications remains the dominant "screening" mechanism for sporadic disease in practice, given the absence of a formal population screening program.

Genetic Counseling

Recommended for patients with bilateral/multifocal renal tumors, hybrid oncocytic/chromophobe histology, or a personal/family history suggestive of BHD syndrome (fibrofolliculomas, spontaneous pneumothorax history) or Cowden syndrome, to guide germline testing (FLCN, PTEN) and cascade testing of at-risk relatives.

Prophylaxis

Not applicable in the pharmacologic sense; nephron-sparing surgical strategy in known predisposition syndromes functions as a form of tertiary/preventive management to preserve long-term renal function against anticipated recurrent tumor development.

14. Other Species / Natural Disease

Taxonomy

Primarily a human disease entity (NCBITaxon:9606); renal epithelial tumors morphologically and molecularly analogous to ChRCC are not well established as a naturally occurring veterinary disease entity in the way, e.g., some hereditary cancer syndromes are documented in dogs.

Comparative/Model Relevance

Comparative biology work has focused on genetically engineered mouse models rather than naturally occurring animal disease (see Model Organisms below). No substantial OMIA (Online Mendelian Inheritance in Animals) entry specific to ChRCC-equivalent naturally occurring disease was identified in this research pass.

Transmission

Not applicable — ChRCC is a non-communicable, non-zoonotic malignancy.

15. Model Organisms

Genetically Engineered Mouse Models

  • Kidney-specific Flcn knockout mouse — proximal-tubule-targeted disruption of Flcn produces renal cysts and early-onset (~6 months), high-penetrance multi-histology renal neoplasia; the majority of tumors in affected mice under 1 year of age are chromophobe RCC-like, with papillary RCC predominating in older knockout mice. Both mTOR and TGF-β signaling pathways are upregulated in Flcn-deficient tumors, directly modeling the human BHD-associated tumor biology, and treatment with the mTOR inhibitor rapamycin for 10 months suppressed tumor growth in this model — providing preclinical rationale for mTOR-inhibitor use in human BHD-associated and sporadic ChRCC (sciencedirect.com/S0085253815609875).

Cell Line Models

  • UOK276 — a spontaneously immortalized human cell line derived from a large chromophobe RCC with regions of sarcomatoid differentiation; hyperdiploid with a modal chromosome number of 49 and evidence of copy-neutral loss of heterozygosity. Genomic and metabolic characterization of UOK276 supports its use as a model for studying aggressive, sarcomatoid-differentiated ChRCC and associated treatment resistance (PMC5561006).

Model Characteristics — Phenotype Recapitulation and Limitations

The Flcn-knockout mouse recapitulates the mTOR/TGF-β pathway activation and histologic spectrum (including a ChRCC-predominant early phenotype transitioning to papillary-predominant with age) seen in human BHD-associated renal tumors, and demonstrates in vivo therapeutic responsiveness to rapamycin — a translationally validated model. A limitation is that this model specifically captures the FLCN-driven hereditary pathway rather than the chromosome-loss/TP53/mtDNA-driven sporadic ChRCC pathway, which currently lacks an equally well-validated genetically engineered mouse model reproducing the characteristic multi-chromosome-loss genomic signature.

Applications

These models support mechanistic study of mTOR pathway dependency (rationale for everolimus use), sarcomatoid dedifferentiation biology and drug resistance (UOK276), and preclinical testing of mitochondrial-pathway-targeted therapeutics given ChRCC's distinctive oxidative metabolic phenotype.

Resources

Mouse Genome Informatics (MGI) for Flcn allele records; Cellosaurus/ATCC for UOK276 and related renal cancer cell line characterization data.

Summary of Suggested Ontology Term Bindings for KB Curation

Category Term
Disease MONDO:0017885 (chromophobe renal cell carcinoma)
Disease (hereditary) MONDO for Birt-Hogg-Dube syndrome; OMIM #135150
Causal genes HGNC:11998 (TP53), HGNC:9588 (PTEN), HGNC:27310 (FLCN), HGNC:3942/12395 (TSC1/TSC2 relevant IDs), MTOR
Cell type CL term for kidney collecting duct intercalated cell (e.g., CL:1000497/CL:0002201)
Anatomy UBERON:0002113 (kidney)
Biological process GO:0031929/GO:0038202 (TOR/TORC1 signaling), GO:0006119 (oxidative phosphorylation), GO:0006977 (DNA damage response via p53), GO:0007004 (telomere maintenance via telomerase)
Phenotypes HP:0000790 (Hematuria), HP:0030057 (Flank pain), HP:0031817 (Abdominal mass)
Treatment NCIT:C15329 (Surgical Procedure), NCIT:C15986 (Pharmacotherapy) with therapeutic_agent CHEBI:68478 (everolimus)

Sources

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Outcome Count
References checked 30
Resolved 30
Unresolved (possible confabulation) 0
Unverifiable 0

All extracted references resolved successfully.